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“Jag vet inte vart jag ska, men jag är på väg”  
Carl Sagan 
   
ABSTRACT 
Although polycystic ovary syndrome (PCOS) is the most common endocrine disorder 
amongst women in reproductive age the etiology and pathophysiology are poorly 
understood. PCOS is characterized by hyperandrogenism, polycystic ovaries and 
ovulatory dysfunction. It is also associated with metabolic disturbances, increased 
luteinizing hormone (LH) secretion and increased muscle nerve sympathetic activity. 
Acupuncture with combined electrical (EA) and manual needle stimulation has been 
demonstrated to improve menstrual frequencies and to reduce androgen and 
glucuronidated androgen metabolite levels in women with PCOS. In a 
dihydrotestosterone (DHT) induced rat PCOS model EA has been shown to improve 
insulin sensitivity, decrease markers of sympathetic activity in adipose tissue and to 
improve ovarian morphology. 
The overall aims of this thesis were to evaluate the effect of acupuncture on ovulatory 
and neuroendocrine as well as metabolic dysfunction in women with PCOS and in 
rats with DHT-induced PCOS, and to search for potential molecular mechanisms 
mediating the effects. In the rat model we also sought to compare acupuncture with 
manual and electrical needle stimulation with regards to their efficacy and signaling 
mechanisms on glucose regulation.  
EA 5 days per week during 4-5 weeks in DHT-induced PCOS rats restored estrous 
cyclicity and reduced elevated protein expression of hypothalamic gonadotropin 
releasing hormone (GnRH) and androgen receptor (AR). Immunohistochemistry also 
revealed a co-localization between the two, indicative of AR activation as a mediator 
of the effects. PCOS women were randomly allocated to either acupuncture with 
combined electrical and manual stimulation or attention control twice weekly for 10-
13 wks. Ovulation frequency was higher in the acupuncture than in the control group, 
but was not accompanied by changes in LH or cortisol secretion patterns. 
Furthermore, most sex steroids; estrogens, androgens and androgen precursors and 
glucuronidated androgen metabolites decreased in the acupuncture group and differed 
from the control group. The effect on ovulatory function has now repeatedly been 
shown in both clinical and experimental studies. Here it appears to be related to 
regulation of sex steroids rather than gonadotropin secretion in women with PCOS 
although the rat data indicates a relation to normalization of hypothalamic aberrations 
after EA treatment. EA 5 days per week during 4-5 weeks normalized insulin 
sensitivity and increased low plasma membrane glucose transporter 4 content in 
skeletal muscle of DHT-induced PCOS rats while glucose tolerance was partly 
improved after manual stimulation. Manual stimulation primarily affected gene 
expression while electrical stimulation primarily affected protein expression, indicating 
different mechanisms of action. This suggests that treatment frequency and 
stimulation modality is of importance and that electrical stimulation of the needles is 
superior to manual stimulation although this needs to be investigated in clinic.  
As shown in this thesis, acupuncture treatment elicits local and systemic effects which 
have the capacity to break the vicious circle of androgen excess, ovarian dysfunction 
and possibly reduced insulin sensitivity in PCOS. It may therefore represent an 
alternative or compliment to standard pharmacological or surgical treatment. 
 
 
  
SAMMANFATTNING PÅ SVENSKA 
Polycystiskt ovariesyndrom (PCOS) är den vanligaste hormonella störningen hos 
kvinnor i fertil ålder. Det drabbar ungefär var tionde kvinna och påverkar både 
reproduktiv och metabol funktion. Dessa kvinnor har ökade nivåer av det manliga 
könshormonet testosteron vilket kan ge symptom som ökad kroppsbehåring och 
acne. De har även oregelbunden eller helt utebliven ägglossning vilket kan medföra 
fertilitetsproblem. De metabola störningarna innefattar okänslighet för insulin samt en 
högre benägenhet för övervikt/fetma. Tillsammans medför detta en högre risk för typ 
2-diabetes och hjärt-kärlsjukdomar.  
Då det i nuläget inte finns någon bot omfattar behandlingen istället medicinsk eller 
kirurgisk lindring av de olika symptomen, vilket ofta involverar biverkningar. Tidigare 
studier har visat att akupunktur har positiva effekter på både reproduktiv och metabol 
funktion med få biverkningar.  
Syftet med denna avhandling var att utvärdera effekten av akupunktur på ägglossning 
och reglering av hormoner från hjärnan (hypothalamus/hypofys), äggstockar och 
binjurar, samt på metabol funktion hos kvinnor med PCOS och hos råttor med PCOS 
som utvecklats genom kontinuerlig tillförsel av manligt könshormon. Ytterligare ett 
syfte var att studera möjliga bakomliggande mekanismer i hypothalamus/hypofys 
avseende reglering av ägglossning samt i muskulatur och fett för reglering av metabol 
funktion som kan förklara effekten av behandling med akupunktur vid PCOS.  
I en randomiserad klinisk studie studerades effekten av akupunktur på reglering av 
ägglossning samt utsöndring av hormoner från hjärna, äggstockar och binjurar. 
Kontrollgruppen träffade en terapeut samma antal gånger men utan 
akupunkturbehandling för att kontrollera för det terapeutiska mötet och tiden det 
innefattar men utan nålinsättning. Akupunkturgruppen hade 28% högre 
ägglossningsfrekvens jämfört med kontrollgruppen. Akupunktur sänkte höga nivåer 
hormoner frisatta från äggstockar och binjurar, samt inhibin B, ett hormon som 
produceras av de växande äggfolliklarna och kan påverka deras hormonproduktion, 
utan någon effekt på hormon som frisätts från hjärnan. Råttor med PCOS fick också 
mer regelbunden ägglossning. Denna effekt kan tänka förklaras av ett samtidigt 
förändrat uttryck av vissa proteiner i hjärnan som reglerar ägglossning. 
Effekten av akupunktur på metabol funktion hos råttor med PCOS visade på en 
normalisering av insulinkänslighet efter elektrisk stimulering av nålarna, vilken ger 
muskelsammandragningar, samt en delvis förbättrad glukostolerans efter akupunktur 
med manuell stimulering av nålarna. Dessa effekter verkar styras av olika mekanismer, 
med förändrat proteinutryck främst i muskulatur efter akupunktur med elektrisk 
stimulering. Våra resultat indikerar även att elektrisk stimulering är mer effektiv än 
manuell, även om vi inte kan utesluta att olikheterna beror på skillnader i 
behandlingstid då manuell stimulering utfördes var femte minut och den elektriska är 
kontinuerlig.  
Sammantaget visar fynden i denna avhandling att akupunktur är fördelaktigt för de 
reproduktiva problemen i PCOS, något som vi demonstrerat i både kliniska och 
djurexperimentella studier. Betydelsen bör undersökas i jämförande studier mot 
nuvarande behandling innan akupunktur kan betraktas som ett eventuellt 
behandlingsalternativ. I de djurexperimentella studierna har vi även sett en upprepad 
positiv effekt på metabol funktion, något som bör överföras och undersökas vidare i 
klinik. 
 
 
 LIST OF PAPERS  
 
This thesis is based on the following studies, referred to in the text by their Roman 
numerals. 
I. Hypothalamic neuroendocrine functions in rats with 
dihydrotestosterone-induced polycystic ovary syndrome: Effects 
of low-frequency electro-acupuncture. Feng Yi, Julia Johansson, 
Ruijin Shao,  Louise Mannerås, Julia Fernandez-Rodriguez, Håkan 
Billig, and Elisabet Stener-Victorin. PloS ONE 2009, 4(8): e6638. 
II. Acupuncture for ovulation induction in polycystic ovary 
syndrome: A randomized controlled trial. Julia Johansson, Leanne 
Redman, Paula P Veldhuis, Antonina Sazonova, Fernand Labrie, Göran 
Holm, Gudmundur Johannsson, and Elisabet Stener-Victorin. Submitted 
III. Intense electroacupuncture normalizes insulin sensitivity, 
increases muscle GLUT4 content, and improves lipid profile in a 
rat model of polycystic ovary syndrome. Julia Johansson, Feng Yi, 
Ruijin Shao, Malin Lönn, Håkan Billig, and Elisabet Stener-Victorin. 
Am J Physiol Endocrinol Metab 2010, 299:E551–E559. 
IV. Electrical vs manual acupuncture stimulation in a rat model of 
polycystic ovary syndrome: Different effects on muscle and fat 
tissue insulin signaling. Julia Johansson, Louise Mannerås-Holm, 
Ruijin Shao, AnneLiese Olsson, Malin Lönn, Håkan Billig, and Elisabet 
Stener-Victorin, PLoS ONE 2013, 8(1): e54357.  
 
 
Copyright © 2010 the American Physiological Society (paper III) 
Copyright © 2009 Feng et al. and 2013 Johansson et al. Open access articles 
(paper I and IV) 
  
 CONTENTS 
 
INTRODUCTION ..................................................................................................... 17 
Polycystic ovary syndrome ............................................................................... 18 
Definition and prevalence ........................................................................................................ 18 
Clinical presentations .............................................................................................................. 20 
Pathophysiology and etiology of PCOS ........................................................... 21 
Androgen excess ..................................................................................................................... 23 
Neuroendocrine dysfunction .................................................................................................... 23 
Ovarian dysfunction ................................................................................................................ 25 
Adrenal dysfunction ................................................................................................................ 29 
Metabolic disturbances ............................................................................................................ 30 
Increased sympathetic activity .................................................................................................. 35 
PCOS – a well orchestrated pathology ............................................................. 36 
Treatment of PCOS .......................................................................................... 38 
Lifestyle modification .............................................................................................................. 38 
Pharmaceutical and surgical alternatives ........................................................ 38 
Acupuncture ..................................................................................................... 41 
Animal models of PCOS ................................................................................... 45 
PRESENT INVESTIGATION ................................................................................... 47 
AIMS ......................................................................................................................... 48 
General aims ..................................................................................................... 48 
Specific aims ..................................................................................................... 48 
METHODOLOGICAL CONSIDERATIONS ............................................................ 49 
Ethics ................................................................................................................ 49 
Animal studies .................................................................................................. 49 
Animal model and study designs ............................................................................................ 49 
 Treatment ............................................................................................................................... 51 
Clinical study .....................................................................................................51 
Included subjects ..................................................................................................................... 52 
Study design ........................................................................................................................... 53 
Interventions ........................................................................................................................... 53 
Sampling and outcome measures ............................................................................................ 55 
Estrous cyclicity and ovulation frequency ...................................................... 55 
Estrous cyclicity (paper I, III-IV) .......................................................................................... 55 
Ovulation frequency (paper II) ............................................................................................... 56 
Assessment of body composition .................................................................... 57 
Body composition (paper II) ................................................................................................... 57 
Dual-energy X-ray absorptiometry (paper III) ....................................................................... 58 
Insulin sensitivity tests ..................................................................................... 58 
Euglycemic-hyperinsulinemic clamp (paper III) ...................................................................... 58 
Insulin sensitivity indexes (paper II) ...................................................................................... 59 
Oral glucose tolerance tests (paper IV) ................................................................................... 59 
Gene expression ............................................................................................... 60 
Real-time RT-PCR (paper IV) ............................................................................................ 61 
Protein expression ............................................................................................ 62 
Immunohistochemistry (paper I, III-IV) ................................................................................ 62 
Western Blot (paper I, III-IV) .............................................................................................. 63 
Hormone pulsatility analyses (paper II) ......................................................... 64 
Mass spectrometry (paper II) .......................................................................... 65 
Statistics ........................................................................................................... 66 
KEY RESULTS AND DISCUSSION ........................................................................... 67 
Effect on ovulatory and neuroendocrine function (paper I-II) ...................... 67 
Acupuncture improves reproductive ovarian function .............................................................. 67 
Acupuncture partly improves neuroendocrine function ............................................................ 68 
Conjunction point for reproductive and neuroendocrine effects ................................................. 71 
Acupuncture on metabolic function (paper III-IV) ........................................ 72 
Acupuncture improves insulin sensitivity ................................................................................ 73 
 Acupuncture affects molecular signaling pathways .................................................................. 74 
Efficacy and mechanisms of manual and electrical stimulation ............................................... 76 
GENERAL DISCUSSION ......................................................................................... 77 
CONCLUDING REMARKS AND FUTURE PERSPECTIVES ................................... 79 
ACKNOWLEDGEMENTS ........................................................................................ 82 
REFERENCES .......................................................................................................... 84 
 
 
ABBREVIATIONS 
 
ACTH Adrenocorticotropic hormone
ADTG Androsterone glucoronide
AD3G Androstane-3α, 17β-diol-3glucoronide
AD17G Androstane-3α, 17β-diol-17glucoronide
AMPK 5' adenosine monophosphate-activated protein kinase
ANOVA Analysis of variance
ASRM American society for reproductive medicine
BMI Body mass index
CGRP Calcitonin gene-related peptide
COC  Combined oral contraceptives
CRH Corticotropin releasing hormone
CT Cycle threshold 
CVD Cardiovascular disease
CYP19a1  Cytochrome P450 aromatase 
DAB 3,3'-Diaminobenzidine
DHEA Dehydroepiandrosterone
DHEA-S  Dehydroepiandrosterone sulphate
DHT 5α-dihydrotestosterone
E1 Estrone 
E2 Estradiol 
 EA Electro-acupuncture
ELISA Enzyme-linked immunosorbent assay
ESHRE European Society for Human Reproduction and Embryology 
FG Ferriman Gallwey
FSH   Follicle stimulating hormone 
GC Gas chromatography
GnRH  Gonadotropin releasing hormone
GnRH-ir Gonadotropin releasing hormone immunoreactive
HPO  Hypothalamic-pituitary-ovarian 
HOMA Homeostasis model assessment
HDB Horizontal limb of the diagonal band
IHC Immunohistochemistry
IR Insulin receptor
LDA Low density array
LH   Luteinizing hormone
MPO Medial preoptic area
MRI Magnetic resonance imaging
MS Mass spectrometry
NIH National institutes of health
NGF Nerve growth factor 
NPY Neuropeptide Y
OGTT Oral glucose tolerance test
  
PCO Polycystic ovaries
PCOS  Polycystic ovary syndrome
PCR Polymerase chain reaction
POMC Pro-opiomelanocortin
PVDF Polyvinylidene difluoride
R Receptor 
RCT  Randomized controlled study
RIA Radioimmunoassay
SHBG Sex hormone binding globulin
RT-PCR Real-time polymerase chain reaction
UPLC Ultra performance liquid chromatography
VIP Vasoactive intestinal polypeptide
VMH Ventromedial hypothalamus
WHR Waist-hip-ratio 
WHO World Health Organization
QUICKI Quantitative insulin sensitivity check index
4-DIONE Androstenedione
 
  
     
  
                                     INTRODUCTION
18 Julia Johansson |  
 
Polycystic ovary syndrome 
 
istorically, good health has been a pillar stone for survival and 
reproduction, and womanhood has always been closely related to the 
unique childbearing capacity. Infertility is defined as the inability to 
conceive after two years of regular trying without contraception, and according 
to World Health Organization (WHO) up to 15% of reproductive-aged couples 
are affected. However, apart from at the clinic, this is often concealed in the 
private sphere of the home. Ovulatory dysfunction represent a large part of 
female infertility. Alongside, prevalence of obesity and the associated 
metabolic syndrome are at constant rise in the modern world. All these factors, 
together with abnormally high levels of androgens, are prevalent findings in 
the female polycystic ovary syndrome (PCOS), a syndrome with psychological, 
social and economic consequences. 
Worldwide, PCOS is the most common endocrine disorder among women of 
reproductive age. It was first described as early as 1935 by Stein and Leventhal and is a 
multifactorial disorder characterized by the co-existence of hyperandrogenism, 
ovulatory dysfunction and, which has given it its name, polycystic ovaries (PCO) (1, 
2). Since then, large efforts has been placed on finding a cause, but also on agreeing 
on a definition and treatment alternatives. The more recent knowledge that women 
with PCOS also are susceptible to the metabolic syndrome assigned it an increased 
level of attention (3, 4). 
Definition and prevalence 
PCOS is defined as a syndrome; hence a single diagnostic criterion cannot solely be 
the subject of diagnosis. It is also a diagnosis of exclusion, meaning that symptoms 
clearly derived from other etiologies should be excluded. Although it has been 
recognized for more than 70 years there is no cohesive definition, and the diagnosis is 
controversial and still causes debate. The most recent and used definitions are the 
Rotterdam, NIH and AES criteria (Table 1). First out was the NIH criteria, agreed on 
in 1990 during an expert conference held at the National Institutes of Health (NIH). 
This definition includes both ovulatory dysfunction (oligo- or anovulation) and 
hyperandrogenism (biochemical or the clinical signs; acne or hirsutism) (5). In 2003, 
on the Rotterdam conference sponsored by European Society for Human 
H 
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Reproduction and Embryology (ESHRE) and American Society for Reproductive 
Medicine (ASRM), the definition was broadened by the addition of polycystic ovaries. 
Two out of three criteria should be fulfilled for diagnosing PCOS (6). In 2006 the 
definition was again confined by the Androgen Excess and PCOS Society (AES) who 
required androgen excess as a fundamental component in the diagnosis, together with 
the addition of at least one of the other components for diagnosis (7).  
 
Table 1. Diagnostic criteria of PCOS. 
A Clinical or biochemical signs of hyperandrogenism. 
B Oligomennorhea, amenorrhea, oligoovulation, or anovulation. 
C ≥12 follicles of 2–9 mm and/or enlarged ovarian volume of ≥10 mL in one or both 
ovaries. 
 
All three definitions are presently used in clinic, however many cases remain 
undiagnosed. In consequence prevalence is difficult to conclude and depends on the 
used definition, as well as the ethnicity of the measured population. This year a 
prevalence study of 527 females from Ankara concluded that the prevalence using the 
NIH, Rotterdam and AES criteria were 6.1, 19.9 and 15.3% respectively (8). A twice 
as large Australian study by March et al in 2010 concluded prevalence up to 8.7, 17.8 
and 12.0% respectively, that is, rather similar numbers (9). Other reports claim 
prevalence of between 6-10% with the NIH and up to 20% with the Rotterdam 
criteria (10). 
Diagnostic criteria NIH 1990 Rotterdam 2003 AES 2006 
 Require: At least two out of: Require: 
Hyperandrogenism (HA)A √ √ √
Ovulatory dysfunction (OD)B √ √ and/or √
PCO morphology (PCO)C  √ and/or √
Possible phenotypes: 1. HA+OD 
1. HA+OD+PCO 
2. HA+OD 
3. HA+PCO 
4. PCO+OD 
1. HA+OD+PCO 
2. HA+OD 
3. HA+PCO 
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The different definitions result in several PCOS phenotypes (Table 1) with a range of 
severity of the syndrome. In classical PCOS, when all three criteria are met, women 
have a metabolically more unhealthy profile than ovulatory PCOS women and the 
mildest form of normo-androgenemic PCOS. The range of this comprises concerns 
when comparing clinical studies using different definitions. After a recent NIH 
workshop on PCOS it was recommended to explicitly report the specific phenotypes 
in all future clinical studies (11, 12).  
Clinical presentations 
Hyperandrogenism 
The most common feature of PCOS, elevated androgen levels, affects around 60-80% 
of PCOS women and can result in the clinical signs; hirsutism, acne, and to some 
extent alopecia (male pattern baldness) (7). Hirsutism is the excess of body hair, with a 
typical male pattern, and can be self-evaluated with a modified Ferriman-Gallwey 
scoring system where a score of eight or above signify hirsutism (13). The prevalence 
of hirsutism differs between ethnic populations but is present in 40-92% of PCOS 
women (14).  Although acne and alopecia are recognized as signs of PCOS, they are 
observed less frequent than hirsutism, and the relations to hyperandrogenism have 
been more questioned (1, 7, 14). Hyperandrogenism is neither necessarily always the 
cause of hirsutism and acne, hence other possible reasons must be excluded. 
Biochemical markers of hyperandrogenism can therefore be useful in the diagnosis of 
PCOS (7). 
Menstrual irregularities 
Menstrual irregularities or oligo-/amennorhea are indicators of, but not equal to, 
oligo-/anovulation. Oligomenorrhea is usually defined as a cycle length of > 35 days 
whereas in amennorhea the intercycle interval exceeds 90 days. The prevalence of 
menstrual irregularities in PCOS depends on the used diagnostic criteria but is 
approximately 75% (7). If using the NIH criteria, of course all patients will experience 
menstrual irregularities. Ultimately, irregular ovulation can cause infertility due to 
difficulties conceiving, and should be acknowledged. 
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Obesity 
Although metabolic dysfunction is not a part of the diagnosis the prevalence of 
women with PCOS being either overweight or obese is high (15). Studies show a great 
variety between populations, and the highest prevalence’s were found in large studies 
from Australia and United states where up to 85% of women with PCOS were 
overweight or obese (16, 17). More wide estimates are somewhere between 38% and 
88% (18). PCOS is also strongly associated with insulin resistance, hyperinsulinemia, 
type 2 diabetes and dyslipidemia (1). PCOS is often said to be associated with central 
obesity and although excess body weight, especially with central or upper body fat 
distribution, has been shown to increase both the metabolic and reproductive 
symptoms of PCOS, the literature is somewhat inconsistent (15). The first study of 
visceral and abdominal fat mass distribution made by magnetic resonance imaging 
(MRI) could not discriminate PCOS from BMI matched controls although insulin 
sensitivity was impaired in the PCOS group, indicating functional differences rather 
than positional in the adipose tissue of PCOS women (19).  This study may be 
criticized due to age differences, but was later supported by our own previous MRI 
measurements with weight- and age pair-wise matched PCOS and controls (20). The 
same year, though, yet another study of not more than 10 lean women with PCOS 
showed decreased visceral fat mass, whilst the most recent study show increased 
visceral abdominal fat (21, 22). Moreover, there is a need of a standardization of the 
anatomical positioning of the abdominal images, since there is now a large variation 
between studies (23). In summary, the MRI results on visceral adiposity in PCOS are 
inconclusive but this may be due to differences in BMI, PCOS definition or 
anatomical positioning of the MRI sections and larger standardized studies should be 
performed. 
 
Pathophysiology and etiology of PCOS 
Despite the high incidence, the etiology of PCOS remains unknown. Due to the 
heterogeneity in the representation of clinical and biochemical features it has been 
debated whether it actually represents one single disorder or several. Symptoms of 
PCOS often manifest around puberty, but the origin may be programmed already as 
early as during fetal development (24-26).  Androgens possess a central position in 
PCOS as is closely related to the ovarian morphology and they are sufficient to cause 
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PCOS like states in both animal models and female-to-male transsexuals (27, 28). It 
has therefore been presented as the likely principal cause of PCOS. Since it is not 
known when or where the pathology actually begins, several different hypotheses are 
presented. Prenatal androgenization represents an established hypothesis of PCOS 
etiology and is based on animal models including monkeys, sheep and rodents where 
prenatal androgenization inflicts several features of PCOS in the offspring (29-32).  
However, in humans, although increased levels of androgens have been found in 
pregnant PCOS women (33), only one study has found increased levels of 
testosterone in umbilical vein blood in infants of PCOS mothers although these levels 
were measured by immunoassays and not mass spectrometry (34). This study had 
though a number of limitations such as small sample size and deficient testosterone 
detection method. On the other hand, a larger prospective study could not 
demonstrate any association between maternal and umbilical cord blood, nor a 
relationship to PCOS (35). However, also this study admits limitations. No 
measurements of placental aromatase activity were made and the late timing of 
measurements might not reflect earlier sensitive periods for androgen exposure. They 
also used adolescent females, whose diagnoses are more problematic (36, 37). The 
latest study where androgens in both maternal and fetal circulation were measured 
with mass spectrometry a relation between the maternal testosterone levels and cord 
blood testosterone was found in male offspring, but not in female. However, maternal 
insulin levels was associated with higher androgen levels in the fetus (38). Prepubertal 
exposure to androgens is yet another hypothesis that originates in the pubertal start of 
symptom manifestation (25, 26), from which several animal models of PCOS has 
been developed (39-41). 
Although not a part of the diagnosis, PCOS is also frequently associated with insulin 
resistance and compensatory hyperinsulinemia (42). Both androgens and insulin, 
which both increase during puberty, are therefore considered to be two key players in 
PCOS and long-standing is the feud concerning which one of these that is related to 
the etiology (25, 26).   
Asides from these, PCOS characteristics such as dysfunctional regulation of 
gonadotropins, intraovarian factors causing altered ovarian steroidogenesis, altered 
adrenal androgen production, increased sympathetic activity, and genetics are 
proposed as causative mechanisms. Genetic studies of PCOS are challenging due to 
the complexity and heterogeneity of the disorder. Studies of heritability show a 
familial aggregation of cases and confirm a strong genetic component but also unique 
environmental influences (43, 44). There are also increased prevalence’s of 
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hyperandrogenemia, metabolic dysfunctions and type-2-diabetes, in first-degree 
relatives of women with PCOS, with PCO morphology being a marker of the 
endocrine and metabolic characteristics (45-47). The etiology may therefore involve a 
genetic component, predisposing some women to PCOS. Gene association studies 
has until now focused on genes involved in TGF-β pathway, insulin signaling or with 
relation to obesity or type 2 diabetes, but there is now more and more focus on 
genome-wide association studies although they demand much larger data sets (44). 
Androgen excess 
Androgens in females are produced both in the ovaries and the adrenals and include 
dehydroepiandrosterone sulphate (DHEA-S), dehydroepiandrosterone (DHEA), 
androstenedione, testosterone and dihydrotestosterone. Testosterone is the most 
potent androgen, while DHEA-S, DHEA and androstenedione is considered to be 
androgen precursors that require further conversion to testosterone, either in 
peripheral tissue or in the ovary, to acquire an androgenic effect. Dihydrotestosterone 
is a peripheral product of testosterone that cannot be aromatized to estradiol (48). In 
PCOS, high circulating levels of androgens, estrogens, sex steroid precursors, and 
glucuronidated androgen metabolites have been demonstrated by gas chromatography 
tandem mass spectrometry (GC-MS/MS) and liquid chromatography tandem mass 
spectrometry (LC-MS/MS)(49). The major androgen excess in PCOS originates from 
the ovaries, but the adrenals contribute to some part (50). Hyperinsulinemia, often 
found in PCOS, inhibit the production of sex hormone binding globulin (SHBG), and 
thereby further contribute to increased levels of free circulating androgens (51). 
Neuroendocrine dysfunction 
Basic neuroendocrine control of follicle development 
Follicle development and concomitant ovulation is under tight control by the 
hypothalamic-pituitary-ovarian axis. Gonadotropin releasing hormone (GnRH) 
neurons dispersed in hypothalamus project into median eminence where they release 
GnRH in a rhythmic pulsatile nature into pituitary portal circulation (52-56). The exact 
timing and control of GnRH secretion is regulated via an interplay of a network of  
different hypothalamic nuclei (57). As a direct result, GnRH, determines 
episodic/pulsatile secretion of gonadotropins; luteinizing hormone (LH) and follicle 
stimulating hormone (FSH) from the anterior pituitary into peripheral circulation 
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where they reach and affect the ovaries (58, 59). The periodicity and amplitude of 
GnRH and gonadotropin secretion is crucial for the entire reproductive axis and vary 
throughout the menstrual cycle (60). Slow GnRH pulses favor FSH while high 
frequency favors LH secretion (61-63). During the follicular phase GnRH gradually 
increase and force a LH surge that triggers ovulation. Following ovulation, a lowering 
of GnRH instead promotes FSH secretion (61). The neuroendocrine secretion is in 
turn controlled by the ovarian steroid production via feed-back mechanisms (64). 
Progesterone, a part of the ovarian sex steroid feedback system, is the main modulator 
of GnRH secretion (65) while estradiol plays a more permissive role with effects on 
pituitary progesterone receptors (66), whereas little is known about any possible 
androgenic modulatory effect. 
Neuroendocrine disturbances in PCOS 
In PCOS the disturbed hypothalamic-pituitary-ovarian (HPO) axis has been 
extensively reviewed (67-70). The most evident neuroendocrine feature regulating 
abnormal ovarian follicle development in PCOS is increased LH pulsatility regarding 
both frequency and amplitude, with relatively low FSH secretion (71-75). Increased 
LH pulse frequency increases theca cell production of androgens while the lower FSH 
levels impairs follicle maturation and consequently ovulation (68). 
The cause of LH hypersecretion in PCOS is probably due to enhanced pituitary 
sensitivity to GnRH, or to changes in GnRH secretion patterns rather than increased 
GnRH secretion (71, 75, 76). It appears to be a result of an acquired impaired 
sensitivity of the hypothalamic pulse generator to the negative feedback of estrogen 
and progesterone in PCOS, possibly by chronic estrogen exposure (71, 74, 75, 77). 
Levels of FSH  in PCOS appears to be low or within the lower follicular range and 
response to GnRH is relatively similar to ovulatory controls (71). There are several 
hypothesis for explaining this, firstly that increased GnRH frequency would favor LH 
secretion, secondly that the inhibitory action of estrogen is preferential for FSH 
suppression in comparison to LH, and thirdly that FSH secretion is not as sensitive to 
GnRH stimulation as LH (71, 78). Moreover, although LH increases are coincident 
with GnRH increases, this is not entirely the case with FSH and there is evidence of 
an additional control system. There is several other factor(s) that could affect FSH 
release with gonadal steroids as well as both gonadal and pituitary produced activins, 
inhibins, and follistatins as possible actors. Moreover,  there is evidence to support 
existence of a separate FSH releasing factor although it has not been isolated (78). 
Altered sex steroid production, metabolic dysfunctions and obesity may all contribute 
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to the changes in LH secretion pattern. Hyperandrogenemia itself may cause 
hypothalamic desensitization to progesterone/estrogen negative feedback signals that 
further increase gonadotropin secretion and hence ovarian androgen production, 
causing a self-driven viscous circle (79, 80). Although increased BMI has a blunting 
effect on LH secretion (72, 75), hyperinsulinemia and insulin resistance  may directly 
or indirectly (by enhancing ovarian gonadotropin stimulated sex steroid production) 
contribute to the abnormal gonadotropin secretion, although the mechanism is not 
clear (81-83).  All these factors increase free androgen levels and contribute to 
anovulation. 
Ovarian dysfunction 
The ovarian dysfunction of PCOS involve both the morphological features of 
polycystic ovaries, with an accumulation of small antral follicles of size 2-9 mm, and 
the clinical consequence of oligo-/anovulation. Moreover there are follicle 
abnormalities where the most consistent feature is androgen hypersecretion (84). 
Abnormalities in ovarian steroidogenesis 
Ovarian steroid production is based on a close collaboration between theca and 
granulosa cells in the growing follicles, and requires gonadotropin input (figure 1) (85). 
Theca cells differentiate around growing follicles and immediately start to respond to 
LH by producing androstenedione from cholesterol, either by the ∆4 or ∆5 pathway. 
The ability to convert androstenedione to estrone and thereafter estradiol is 
exclusively acknowledged aromatase cytochrome P450 hydroxylase (CYP19) 
containing granulosa cells, and is under the control of FSH (86). Ovarian originating 
testosterone, which corresponds to about 75% of the circulating pool, is converted 
from androstenedione by 17β-hydroxysteroid dehydrogenase (17β -HSD) type V that 
mainly is expressed in the theca cells (87). Other isoforms of 17β –HSD, type I and II, 
are found in granulosa cells but is believed to be more associated to the conversions 
between estrone to estradiol (88). The circulating testosterone therefore mostly 
originates from theca cells.  
LC-MS/MS measurements of follicular fluid of PCOS women have shown increased 
levels of both individual and total pool of androgens (DHEA, androstenedione, 
testosterone, androstanedione) and lower levels of individual and total pool of 
estrogens (estrone, estradiol, estriol) (89). Their increased production of testosterone 
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and androstenedione seems to be mainly via the ∆5 pathway and DHEA, although 
data is scarce (90).  
Figure 1. Steroid synthesis in the ovary   
  
Women with PCOS appear to have theca interna hyperplasia, a thicker layer of the 
theca cells, which seem to be responsible for their increased androgen steroidogenesis. 
Moreover, each theca cell has increased expression of LH receptors, with increased 
susceptibility to LH stimulation (69, 86, 91).  But there are also evidence supporting 
that hypersecretion of LH is not the primary cause of the abnormal steroid 
production in theca cells of PCOS ovaries, instead other intrinsic factors are primary 
responsible (92, 93). Expression and activity/efficacy of key enzymes involved in the 
steroidogenesis in theca cells has been shown to be increased in PCOS, with some 
support of a genetic origin (89, 91, 94, 95). Altogether, both number of androgen 
producing cells as well as their intrinsic and gonadotropin stimulated activity is 
increased in PCOS. 
In granulosa cells the conversion of androgens to estrogens is dependent of FSH 
induced aromatase activity, which is increased in preovulatory follicles compared with 
non-ovulatory follicles (85). In PCOS, even though they have arrested follicular 
development, their steroidogenesis is active with increased aromatase activity and 
progesterone production compared with follicles of similar size from ovulatory 
women with or without polycystic ovaries (96). Same applies to the estradiol 
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production, which is typically increased in true anovulatory PCOS women with 
hyperandrogenism, but not in ovulatory subjects with polycystic ovaries (96-98). This 
creates a dividing line dependent on ovulatory status, where anovulatory subject have 
both hypersecretion of androgens and estrogens, while ovulatory subjects have solely 
hypersecretion of androgens. Moreover, testosterone itself has been shown to have a 
direct stimulatory effect on aromatase expression which could provide an explanation 
to this effect (99). 
Hyperinsulinemia, one of the main features in PCOS, seems to trigger the thecal 
abnormalities and amplify ovarian steroidogenesis in both theca and granulosa cells 
(83, 100, 101). Reducing insulin secretion by metformin has been shown to decrease 
enzyme activity and circulating free testosterone while increasing SHBG levels (102). 
In lean women with normal insulin sensitivity reducing insulin levels was associated 
with decreased androgen levels, which also suggest increased insulin sensitivity in the 
androgenic pathway within the ovary (103). 
Impaired follicle development 
PCOS is a common reason for infertility and explain the largest part of WHO-II 
anovulation (104).  The ovulatory dysfunction in PCOS can be ascribed the disturbed 
follicular development of excessive early follicular growth and abnormal later stages 
with arrested follicle growth well before expected maturation (105). This pattern of 
follicular growth with failure in the selection of a dominant follicle for ovulation, 
results in one of the hallmarks of PCOS, the PCO morphology.  
PCOS ovaries were during the 80s found to contain 2-3 times as many small (2-5 mm) 
growing preantral follicles (106). This was later repeated where biopsies of both 
ovulatory and anovulatory PCO had increased density of small preantral follicles 
(107). Although there is an increased amount of growing follicles, it does not seem to 
cause premature depletion of the follicle pool. This may be explained by an 
concurrent and deviant decreased level of atresia of preantral follicles seen in PCOS 
(108). The arrested follicle development could be explained by their low FSH levels, 
not reaching the threshold needed to stimulate a normal maturation process (84). In 
addition, the hypersecretion of LH might suppress FSH function and cause premature 
luteinization of granulosa cells that is detrimental for follicle development and 
ovulation (109, 110). Granulosa cells from anovulatory PCOS has been shown to be 
significantly more responsive to LH than size matched control follicles which indicate 
prematurity (98). 
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Both androgens and insulin probably play a role in the impaired follicle development 
in PCOS. Anovulatory and ovulatory PCOS can be discriminated by insulin resistance 
and hyperinsulinemia, where these are more common features of anovulatory PCOS. 
Insulin may therefore contribute to the follicle dysfunction in PCOS, but it is probably 
not the only factor (96). Androgens impair follicle development by contributing to an 
exaggerated follicular growth at the early gonadotropin-independent stage. At later 
stages they work synergistically with LH and insulin by inhibiting granulosa cell 
proliferation or disrupting estrogen and progesterone synthesis, hence impeding 
follicular maturation (50). 
There are also local selectors for follicle recruitment and growth within the ovary that 
might contribute to their impaired follicle development. AMH is expressed by early 
antral and preantral follicles, but not in later stages of development, and reflects the 
size and activity of the follicular pool (111, 112). There is also evidence of its 
involvement in the regulation of recruitment of primordial follicles into the growing 
pool, presumably by decreasing the granulosa cell sensitivity to FSH (113). Adding 
AMH to ovarian cultures reduces the number of growing follicles, while if removing 
the gene the proportion increases (114, 115). In the small primordial and transitional 
follicles of anovulatory PCOS, AMH protein expression is reported to be reduced 
(116). This may contribute to the inappropriate recruitment of growing follicles. 
Additionally in both circulation and antral follicular fluid of PCOS women, AMH 
levels are increased and these are associated with poor reproductive responsiveness to 
treatment (117-123).  These high circulating levels may only be a reflection of their 
increased pool of granulosa cells in the follicle and not increased expression. Since 
high levels of AMH are associated with lower levels of FSH and estradiol it has been 
suggested that the AMH excess is involved in the lack of FSH-induced aromatase 
activity that is characteristic of follicular arrest in PCOS (122, 124). Testosterone 
exposure down-regulates AMH expression in granulosa cells of small bovine follicles 
in culture and could possibly represent a mechanistic origin of PCOS (125). 
Ovarian inhibins are expressed in ovaries and acts as modulators to suppress FSH 
levels. As a response to increased FSH levels inhibin B is increasingly expressed 
during early follicular phase in small developing follicles, while inhibin A is selectively 
produced in the dominant follicle. Inhibin B therefore correlates to total follicle 
number and may be a marker of follicle quality (126). But inhibins also have a local 
effect and stimulate androgen production synthesis in theca cells for estradiol 
production (126-128). In PCOS most studies does not find any basal differences in 
circulating inhibin B, but an abnormal and increased response to FSH. The normal 
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basal levels may be explained by the diminished FSH secretion in PCOS or that the 
follicle quality is lower and the increased response to FSH could simply be due to the 
increased number of preantral and small antral follicles (127-130). Moreover, follicular 
arrest in PCOS is associated with reduced levels of both inhibin A and B in follicular 
fluid, which both could explain the normal circulating levels even though the 
increased pool follicles, but also making these possible actors in the impaired follicle 
development (131). There is low evidence of any diagnostic value of circulating basal 
inhibin B measurements in PCOS (127, 132). 
Taken together, impaired folliculogenesis and steroidogenesis in PCOS seems to be 
multifactorial and is probably influenced by extra ovarian factors such as androgens, 
insulin, neuroendocrine alterations and intraovarian local and intrinsic factors as well 
as genetics. 
Adrenal dysfunction 
The adrenal cortex is the final and crucial part of the hypothalamus-pituitary-adrenal 
axis. It secretes both cortisol and androgens, such as DHEA, DHEA-S, 
androstenediol, testosterone and 11β-hydroxyandrostenedione, as a response to 
pituitary ACTH after hypothalamic corticotrophin releasing hormone (CRH) release 
(133). PCOS appear to have an increased adrenocortical activity resulting in increased 
levels of adrenal androgens with a relation to altered cortisol metabolism (134-137).  
Adrenals contribute to PCOS hyperandrogenemia  
Although the main part of androgen excess in PCOS origins from the ovaries 20-50% 
of patients also have an adrenal hyperandrogenism. DHEA-S, the sulfated form of 
DHEA, has clinically been the marker of adrenal androgen excess since 97-99% of the 
circulating levels origins from the adrenals as compared with testosterone where only 
around 25% origins from the adrenals. However, it may not always reflect the 
adrenocortical secretion of other adrenal products, either basally or as a response to 
ACTH (138). Serum levels of ACTH appears to be normal and, although the 
mechanism is not completely clear, data favors that the adrenal androgen excess in 
PCOS is more related to adrenal hyper responsiveness to ACTH than pituitary hyper 
responsiveness to CRH (139, 140). Altered enzymatic activity of cytochrome P450 
17α-hydroxylase (CYP17) has also been reported and been suggested as a contributing 
factor to the adrenal hyperandrogenism (140, 141). 
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Cortisol 
Glucocorticoids redistribute adiposity to central depots, increase the size and number 
of fat cells and may play a role in the development of metabolic syndrome (142). 
Cortisol is released in bursts from the adrenal gland with amplitude modulation rather 
than frequency modulation to control the nyctohemeral rhythm (143). Even though 
there is an increased ACTH response to CRH in obesity, the cortisol response seems 
unaltered. Instead more evidence point towards an altered peripheral cortisol 
metabolism with tissue specific cortisol excess (144-146).  In PCOS plasma levels of 
ACTH and the response to CRH seems to be normal, suggesting normal pituitary 
responsiveness (138). Some, but not all data, indicate increased cortisol levels, both 
basally and ACTH stimulated, in PCOS (136, 147-149). However, there are evidence 
for increased peripheral cortisol metabolism and increased clearance from blood (134, 
150-152). There has been focus on the activity of the enzyme 5α-reductase, which was 
found to be increased in both lean and obese PCOS and could explain part of the 
increased levels of cortisol metabolites (134, 151).  Increased 5α-reductase has also 
been shown to be correlated to both HOMA-IR and BMI, indicating that insulin 
enhances 5α-reduction (151). Moreover, treatment of obese Zucker rats with the 
thiazolidinedione rosiglitazone, an insulin sensitizer and PPARγ agonist, significantly 
decreased 5α-reductase (153). One hypothesis suggests that the increased rate of 
cortisol metabolism per se would decrease the negative feedback on the HPA axis to 
compensate for the reduced levels of cortisol by increasing the adrenal drive and 
thereby also the androgen production. However, recent studies showing similar 
cortisol half-lives and similar pioglitazone- (another thiazolidinedione and insulin 
sensitizer) -induced reduction in 5α-reductase activity without significant effects on 
adrenal androgen or cortisol secretion, does not support this hypothesis (148, 154). 
Metabolic disturbances 
Insulin resistance with compensatory hyperinsulinemia is almost, but not quite, a 
universal feature of PCOS with prevalence between 65-80% in lean and up to 95% in 
obese subjects (155, 156). It is worsened by obesity since the obese PCOS population 
also add on the burden of insulin resistance that is related to excess adiposity (157, 
158). Lean women with Rotterdam diagnosed PCOS have been found to be equally 
insulin resistant as obese controls while the insulin resistance of obese women with 
PCOS were even worse than the obese control group. Also, BMI had a more potent 
negative impact on insulin resistance in PCOS than in controls. Altogether, PCOS 
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have both an worsened intrinsic and extrinsic (BMI inflicted) insulin resistance (159). 
The metabolic disturbances in PCOS seem to be foremost inflicted on the classic 
hyperandrogenemic phenotypes of PCOS, whilst the anovulatory women with normal 
androgen levels are metabolically relatively healthy (8, 160-162). But it is not 
established whether the hyperinsulinemia related to insulin resistance causes 
hyperandrogenism or vice versa (42). 
The metabolic syndrome is a constellation of multiple risk factors that consist of 
atherogenic dyslipidemia, elevated blood pressure, elevated plasma blood glucose, 
central obesity, a protrombotic state, and a proinflammatory state. The metabolic 
syndrome is associated with a ≈2-fold increased risk of cardiovascular events and a 
≈5-fold risk for developing diabetes and the underlying risk factors are abdominal 
obesity and insulin resistance (163). The common features of obesity and insulin 
resistance in PCOS should subsequently result in increased prevalence of metabolic 
syndrome. Studies are inconsistent with varying prevalence, although most showing 
increased prevalence of metabolic syndrome with positive correlations to weight, age, 
hyperandrogenemia and low SHBG (3, 4, 164-167). These variations may be related to 
the studied population, PCOS definition, age and BMI. 
PCOS is also related to high prevalence of impaired glucose tolerance and type 2 
diabetes, with an accelerated development of type 2 diabetes from impaired glucose 
tolerance (167-169). Altogether, if above mentioned risk factors are not properly 
handled they will potentially lead to cardiovascular disease (CVD) later in life (170). 
Although increased prevalence of several risk factors, including increased serum 
concentration of CVD risk biomarkers, are found in PCOS women, hard evidence for 
increased CVD morbidity and mortality is inconclusive and long-term prospective 
studies are needed (1, 10, 11, 171, 172). 
Basic insulin signaling and glucose transport 
Insulin dependent glucose transport and metabolism in skeletal muscle and adipose 
tissue are regulated via the insulin-signaling pathway in which the glucose transporter 
4 (GLUT4) is translocated into the plasma membrane to enable glucose influx from 
the blood. Signal transduction is mediated via a complex network of phosphorylation 
cascades after an initial activation of the insulin receptor substrate 1 (IRS-1) when 
insulin is docking the insulin receptor (173, 174) and is visualized in Figure 2. IRS-1 
then activates phosphatidylinositol 3-kinase (PI3K) that further phosphorylates 
membrane phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-
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3,4,5-triphosphate (PIP3). These activates phosphoinositide-dependent protein 
kinases (PDK-1 and 2) which can activate protein kinase B (Akt) that further 
phosphorylates Akt substrate of 160 kDa (AS160), and atypical protein kinase C λ and 
ζ (PKC λ/ ζ). These lastly stimulate GLUT4 translocation to the cell membrane (42). 
Figure 2.  Signaling pathway resulting in the translocation of the glucose transporter GLUT4 in response 
to insulin. Akt: protein kinase B , AS160 – akt substrate of 160 kDa, IR – insulin receptor, IRS-1 – 
insulin receptor substrate 1, GLUT4 – Glucose transporter 4, PDK  – phosphoinositide-dependent protein 
kinase, PI3K – phosphatidylinositol 3-kinase, PKC  – atypical protein kinase C, PIP2  – 
phosphatidylinositol-4,5-bisphosphate, PIP3 – phosphatidylinositol-3,4,5-bisphosphate. 
Basic insulin independent glucose transport 
Glucose transport in skeletal muscle is regulated by at least two distinct signaling 
pathways that comprise the insulin stimulated signaling and the contraction/exercise 
insulin independent signaling (175-177). Both acute and chronic exercise 
training/contractions stimulate GLUT4 translocation, glucose uptake and insulin 
sensitivity (175-181).  
The effect of acute contractions on glucose uptake is insulin independent with an 
additive effect to insulin stimulation and probably involves several different 
mechanisms (179, 180, 182).  Acute exercise has also been shown to increase GLUT4 
translocation by recruitment from a different intracellular pool than insulin 
stimulation, further indicating different mechanisms (182, 183). One mechanism may 
involve an interaction with distal insulin signaling by a convergence of different 
signaling branches. Although the converging link between the insulin signaling 
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pathway and insulin independent pathway has not been shown it has been speculated 
to be AS160 (177, 184).  Other likely candidates involved in the contraction response 
of increased glucose uptake are cytosolic Ca2+, 5' adenosine monophosphate-activated 
protein kinase (AMPK), and adiponectin (175, 176, 185, 186).  
Repeated exercise training may restore protein signal transduction earlier in the insulin 
signaling pathway as proximal as PI3K and possibly also IRS-1 and 2 although data 
regarding IRS proteins are scanty (181, 187). MAPK’s and/or AMPK may be 
involved in the cellular adaptations to chronic exercise with regards to increased gene 
expression (175-177, 181, 186). 
Insulin resistance in PCOS 
In general, insulin resistance can be defined as when a normal amount of insulin 
produce a less than normal biological response. This includes reduced responsiveness, 
reduced sensitivity, or both. In reduced responsiveness the maximal response to 
insulin is reduced, whereas in reduced sensitivity the acquired amount of insulin 
needed to obtain a certain response in increased (188). Sensitivity is usually explained 
by receptor binding or phosphorylation, whilst responsiveness is explained by post-
receptor events (189).  
Whole body insulin resistance is normally characterized by increased circulating levels 
of insulin, both basally and after a glucose load (190). The euglycemic 
hyperinsulinemic clamp is the golden standard method to assess insulin resistance, but 
it is impractical in clinic and oral glucose tolerance tests (OGTTs) or HOMA-ir 
indexes are instead common. But even though a normal result is obtained by an 
OGTT, insulin resistance could be concluded by HOMA-ir or clamp assessments 
(191, 192). Hence, to determine and diagnose insulin resistance, one single method 
may not be sufficient. 
Muscle tissue corresponds to the uppermost part of whole body insulin stimulated 
glucose uptake, while adipose tissue only accounts for a small fraction (193). However, 
this does not mean that adipose tissue is not involved in whole body insulin 
sensitivity. On the contrary, adipose tissue seems to indirectly induce insulin resistance 
in other insulin target tissues through cross-talk mechanisms (194). Particularly 
visceral obesity causes insulin resistance that appears to be related to lipid 
accumulation in liver and induction of inflammation (195). In both lean and obese 
women with PCOS whole body insulin sensitivity (half-maximal insulin response) and 
responsiveness (maximum insulin response) has been shown to be decreased (190). It 
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has been suggested that obese women with PCOS in addition have decreased hepatic 
insulin sensitivity for endogenous glucose suppression, although this was not 
supported by later studies using updated tracer techniques (196, 197). With decreased 
insulin sensitivity, pancreatic insulin production increases, and an acquired pancreatic 
β-cell dysfunction is required for later development of type 2 diabetes. PCOS women 
display β-cell dysfunction independent of obesity, but more pronounced if having a 
first-degree relative with type 2 diabetes (190). Moreover, the size of subcutaneous 
adipocytes has been shown to be increased and serum adiponectin decreased in 
women with PCOS. Adipocyte size together with adiponectin and waist 
circumference was also strongly associated to insulin sensitivity (20). 
Insulin resistance in muscle 
Insulin resistance in muscle is defined as impaired glucose transport and muscle 
glycogen synthesis in response to insulin (195). Ciaraldi et al found that glucose 
transport in cultured myocytes originating from PCOS women have impaired insulin 
responsiveness but not sensitivity (158). However, no differences in GLUT4 levels 
have been reported (158, 171). Courbould’s in vivo experiments of skeletal muscle 
biopsies during a clamp have shown a decreased IRS-1 associated PI3K activity, 
independent of obesity, along with decreased insulin mediated glucose disposal. This 
change was seen only early in the clamp. No change in insulin receptor (IR), IRS-1 or 
the p85 subunit of PI3K abundance was discovered, which is indicative of a defect in 
downstream signaling patterns. Levels of IRS-2 were though increased, which might 
reflect a compensatory effect (198). Following the insulin signaling pathway further 
downstream, another study found reduced levels of insulin stimulated 
phosphorylation (activation) of Akt and AS160 after a clamp with physiological doses 
of insulin, mainly measuring insulin sensitivity. They did not find decreased IRS-1 
associated PI3K activity, which is consistent with the Courbould study, since here they 
took their biopsies after 3h of insulin infusion (199). This was not supported by the 
later Ciaraldi study who found no alterations in Akt activation (200). The reason may 
be that they used maximal insulin stimulation which might have masked this 
difference. To study whether the defects in skeletal muscle of PCOS is an intrinsic 
effect or environmentally induced, differentiation of myoblast into myotubes and then 
culturing them for generations has been implemented. Insulin resistance seems to be 
an acquired feature but some of the abnormalities, such as increased inhibitory 
phosphorylation of IRS-1 and an increase of IRS-1 abundance, that might have been a 
compensatory effect, may be intrinsic (201, 202).   
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Insulin resistance in adipose tissue 
Insulin resistance in adipose tissue is defined as impaired glucose transport and 
inhibition of lipolysis in response to insulin (195). One consistent feature of PCOS 
adipocytes is decreased insulin sensitivity (191, 196, 200), indicating altered receptor 
binding or phosphorylation (170). IR number and insulin binding appears though to 
be normal, although the levels of the IR transmembrane β-subunit have been reported 
to be lower in one study (196, 203, 204). Some studies have found reduced insulin 
responsiveness indicating also post-receptor alterations (165, 205) that probably is 
related to the reduced levels of GLUT4 in PCOS adipocytes (204, 205). This data has 
been challenged and was contradicted by a study that did not find lower levels of 
GLUT4 in PCOS adipocytes (158). In isolated adipocytes no major differences in 
expression or activity of proteins downstream of IR in the insulin signaling pathway 
has been found. But in adipose tissue increased levels of PI3K together with impaired 
phosphorylation pattern of IRS-1 have been reported (158, 189). The drawbacks of 
these studies are that measurements were made after maximal insulin stimulation 
(responsiveness) and in basal state, respectively. This means that neither of them really 
represents, or explains, the most prominent feature of decreased sensitivity.  
Increased sympathetic activity 
The autonomic nervous system consists of two divisions; the sympathetic and the 
parasympathetic nervous systems, and is controlled by the neurotransmitters 
noradrenaline and adrenaline and activation of adrenergic receptors. In a normal, 
healthy state, a fine balance between the two divisions ensures homeostasis. Many of 
the classical components of PCOS such as polycystic ovaries, insulin resistance with 
related hyperinsulinemia, central obesity and hypertension are associated with 
increased sympathetic activity (206-209). It has therefore been suggested to account 
for at least a part of the syndromes etiology (207, 208, 210). That increased 
sympathetic innervation of the ovaries might contribute to the impaired follicular 
development in PCOS is supported by clinical evidence such as increased density 
catecholaminergic nerve fibers, increased NGF production and altered catecholamine 
metabolism and/or uptake in PCOS ovaries (208, 211-213). Heart-rate recovery after 
a bout of exercise and heart-rate variability can be used as non-invasive markers of 
autonomic function. Measures in PCOS women indicate that they have decreased 
dynamic activity in their autonomic function, possibly by decreased activity in the 
parasympathetic component and increased in the sympathetic component (214-216).  
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These are though indirect measures and their accuracy may be questionable. We have 
though demonstrated by microneurography (MSNA), which is a direct and reliable 
measure of muscle sympathetic nerve activity, that PCOS women have an increased 
sympathetic nerve activity that is correlated to high levels of testosterone (217). 
PCOS – a well orchestrated pathology 
Androgens play a central part, perhaps even the leading part, in the pathology of 
PCOS. Androgens alone can affect many of the systems that are impaired in the 
syndrome, and are sufficient to cause PCOS like states in both animal models and 
female-to-male transsexuals (27, 28, 30-32, 218-220). But these alterations can 
themselves further increase hyperandrogenemia. Consequently a vicious circle is 
created where the individual pieces may augment each other, and it is not clear where 
it started. In this section I will try to merge these pieces, similar to a “connect the 
dots” puzzle, illustrated in fig. 3. Firstly, I would like to point out that the effect of 
androgens can be mediated either directly via the androgen receptor, or through the 
aromatization to estrogen. 
Hyperandrogenemia in PCOS originating mainly from the ovaries and can have 
central effects by increasing gonadotropin secretion via effecting sex-steroid feed-back 
systems as well as enhancing the effect on ovarian gonadotropin stimulated sex steroid 
production (50, 79, 80). Androgens also directly impair follicle development and 
maturation and thereby contributing to the PCO morphology and thereby the ovarian 
pool of androgen producing cells (50). Both of these will further drive ovarian 
androgen production and increase levels of free circulating androgens. Additionally, 
although the mechanism is not completely clear, increased adrenal androgen 
production contribute to the androgen excess in PCOS (139, 140). 
Androgens are also associated with an atherogenic blood lipid profile, enlarged 
adipocyte size and peripheral insulin resistance although the androgen excess may not 
be the primary cause of their insulin resistance (20, 221, 222). Moreover, together with 
obesity this increases the risk of type 2 diabetes and CVD (15). Similar to androgens, 
insulin resistance and hyperinsulinemia enhances ovarian gonadotropin stimulated sex 
steroid production (50, 81-83) and may contribute to the abnormal gonadotropin 
secretion although the mechanism is not clear (81-83).  Hyperinsulinemia also 
decrease liver production of SHBG which increases the amount of bioavailable free 
circulating sex steroids (51).  
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PCOS is related to increased muscle sympathetic activity and of special interest is that 
testosterone concentration was found to be a strong independent predictor (217). 
Increased sympathetic nerve activity is related to insulin resistance with related 
hyperinsulinemia, central obesity and hypertension (206-209) and might contribute to 
the increased cardiovascular risk (217). There is also evidence that support an 
increased sympathetic nerve activity to the ovaries (208, 211-213) that may further 
drive androgen production and PCO morphology (223).  Apart from above described 
factors there is a strong genetic component with familial aggregation of cases and 
symptoms (43, 44), that probably is involved in the etiology of PCOS. Altogether, 
PCOS is a coordinated pathology containing factors that strongly influence each 
other, making it difficult to separate the etiology. 
Figure 3. Summary of the PCOS pathophysiology. 1) Ovarian androgens are the main source of 
hyperandrogenemia in PCOS. Hyperandrogenemia have both a direct effect on the ovarian alterations as 
well as 2) an increasing effect on pituitary LH pulse frequency and amplitude with relative low FSH 
secretion. 3) Further, adrenal androgens contribute to PCOS androgen excess.4) Insulin resistance with 
compensatory hyperinsulinemia enhances ovarian androgen production as well as 5) decreasing production of 
SHBG in the liver, both increasing the pool of bioavailable androgens. 6) PCOS is also associated with 
increased muscle sympathetic nerve activity that is related to high testosterone, insulin resistance and obesity 
7) Genetic defects probably contribute to the pathology of PCOS. LH – luteinizing hormone, FSH – 
follicle stimulating hormone, SHBG – sex hormone binding globulin, DHEA – Dehydroepiandrosterone, 
DHEAS – Dehydroepiandrosterone sulphate. 
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Treatment of PCOS 
Due to the lack of knowledge about the etiology of PCOS and the heterogeneity of 
the syndrome no cure can currently be offered. Women are instead treated in a 
symptom oriented manner, often for long duration, with adverse effects. 
Lifestyle modification 
Lifestyle modifications, including diet and exercise, are frequently recommended as a 
first-line treatment in the large population of overweight and obese PCOS women. It 
improves several of the key features of PCOS such as body composition, 
hyperandrogenism and  cardiometabolic profile, including insulin sensitivity and blood 
lipids, but also autonomic function and inflammatory pattern  (224-233). The effect 
on reproductive function is though controversial and evidence from systematic 
reviews of randomized controlled studies (RCT’s) is limited. However,  it may 
improve ovulatory function and pregnancy (225, 227, 230, 234, 235) alone or together 
with clomiphene citrate (CC) (229). Even a modest (5%) weight reduction has been 
reported to improve metabolic and reproductive function (236). Although exercise 
training in overweight/obese PCOS women improves insulin sensitivity it does not 
seem to be able to normalize it to overweight control levels, making other treatment 
for IR sometimes still considered required (228). The effect of exercise on insulin 
sensitivity seems to be via mechanisms unrelated to weight loss (228) or mitochondrial 
function (224). Since skeletal muscles represent such large part of the body mass and 
might account for up to 90% of the insulin-stimulated uptake, most focus of the 
effect of exercise has been on muscle adaptations (237). 
Pharmaceutical and surgical alternatives 
For PCOS women not trying to conceive, combined oral contraceptives (COC) are 
commonly used for menstrual disorders associated with PCOS.  COC reduce 
hyperandrogenism by suppressing pituitary LH hormone secretion and ovarian 
androgen secretion while increasing circulating SHBG. Consequentially, they improve 
signs of hyperandrogenemia in form of acne and hirsutism (238).  Although limited 
evidence and lack of long-term effects, COC may have negative impact on metabolic 
function and insulin resistance, especially in obese PCOS patients (158, 238). 
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Insulin sensitizers 
Insulin resistance and hyperinsulinemia have implications for both ovarian function 
and long-term health related to metabolic abnormalities. Considering to treat women 
with PCOS with insulin sensitizers are therefore common and logical (239).  
Metformin, originally used world-wide for the treatment of type 2 diabetes, inhibits 
hepatic glucose output and increases insulin sensitivity and glucose uptake in 
peripheral tissues (240). It is now also commonly used in PCOS for improving insulin 
sensitivity and several studies show decreased insulin,  androgen and LH levels, 
improved LH pulsatility by reduction of amplitude, cortisol secretion frequency and 
potential effects on reproductive function (81, 241-247). Adverse effects include 
gastrointestinal distress such as nausea, abdominal pain and diarrhea and 
malabsorbtion of vitamin B12 (241, 242). Although commonly used it is currently not 
licensed as treatment for PCOS (242). 
Thiazolidinediones such as pioglitazone and rosiglitazone was initially used to treat 
type 2 diabetes and improve peripheral insulin sensitivity but has later also been used 
to treat PCOS. Similar to metformin they increase insulin sensitivity and they may 
decrease free testosterone and DHEA levels but without any effect on LH pulsatility. 
Since, by contrast to metformin, they tend to increase weight and cause serious 
adverse effects, they are not recommended for women trying to conceive, at risk for 
pregnancy or with PCOS (1, 197, 239, 248, 249).  
Ovulation induction 
Treatment of first choice for ovulation induction in women with PCOS attempting to 
conceive is clomiphene citrate (CC) (245). CC is a non-steroidal compound that 
resembles an estrogen, enabling it to block hypothalamic estrogen receptors and the 
estrogenic negative feedback and thereby induce a FSH and LH discharge from the 
pituitary leading to ovulation (250-252). Predictors of outcome are mainly obesity and 
hyperandrogenemia but also mean ovarian volume and cycle history (253).  Studies 
have shown an ovulation rate of 60-85% and a pregnancy rate of 30-50% after six 
ovulatory cycles; if ovulation cannot occur at the highest dose of 150 mg/day they are 
designated as CC resistant (approx. 20%) (253, 254). Ovarian hyperstimulation, 
multiple gestations and spontaneous abortions belong to the adverse effects of CC 
stimulation, although rare (245, 250). The reports on the efficacy of metformin in 
combination or as alternative to CC in PCOS and reproductive function is 
inconclusive and the latest Cochrane report from 2012 concludes an association with 
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higher clinical pregnancy rate compared with placebo and in combination with 
clomiphene citrate versus clomiphene alone (255). However, there was no 
improvement on pregnancy outcome (live births) either used alone or in combination 
with clomiphene, in contrast with clomiphene alone (255, 256). A following systematic 
review and meta-analyses concluded that there is insufficient evidence to confirm the 
superiority of either treatment but that metformin is associated with more adverse 
effects (257). 
If CC fails, gonadotropin (FSH) therapy or laparoscopic ovarian surgery is considered 
as further treatment. Low dose protocols of FSH are now recommended for PCOS to 
reduce the risk of excessive follicle development/multiple pregnancies (< 6%) and 
ovarian hyperstimulation syndrome (<1%) that were more frequent with traditional 
dose protocols. The efficacy manifests a 70% ovulation rate and a 20% pregnancy rate 
(245) but the treatment are costly and requires intensive ovarian monitoring (247).  
Laparoscopic ovarian surgery (LOS) was initiated with ovarian wedge resection and 
has won ground with the rise of laparoscopy and other minimally invasive surgery 
such as laparoscopic ovarian drilling by electrocautery or laser. LOS has the advantage 
over gonadotropin therapy by lower risks of higher order multiples and ovarian 
hyperstimulation syndrome although a surgical option always include intra- and 
postoperative risks (247, 258, 259). The latest Cochrane review reported a pregnancy 
rate between 25-51% and live birth between 24-44% with no significant difference 
compared to CC or gonadotropins (260). LOS can be recommended for patients that 
hypersecrete LH since it reduces LH, LH/FSH, LH amplitude and pituitary 
responsiveness to GnRH in addition to reduction of androgens and estrogens, long 
term (261, 262). The mechanism behind LOS is yet unknown but speculations include 
destruction of androgen producing tissue and the peripheral conversion of androgens 
to estrogens (245, 260). Another possible mechanism may be modification of ovarian 
sympathetic nerve activity, since PCOS is associated with sympathetic overactivity and 
ovarian nerve growth factor (NGF) excess (207). 
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Acupuncture 
Hypothetical mechanism 
Acupuncture is widely practiced and is now also accepted in the western world for the 
treatment or adjunct treatment for more and more conditions (263). It is a relatively 
safe treatment with few side effects (264). 
Acupuncture originates from Traditional Chinese Medicine where fine needles is 
placed in the skin and underlying muscle at specific areas of the body, so called 
acupoints. When placed, needles are stimulated manually, so called manual 
acupuncture, by rotating or perturbing needles up and down. Needles may also be 
stimulated electrically by applying an electrical field and passing an electrical current 
between two needles, so called electro-acupuncture (EA). Low-frequency (1-15Hz) 
electro-acupuncture with an intensity that evokes muscle contractions is believed to 
achieve biological processes that resemble the effects of exercise. Acupuncture from a 
western scientific perspective can’t confirm point specificity and instead explain the 
effect with the activation of afferent sensory nerve fibers at appropriate segmental 
level (265, 266). Acupuncture activates and modulates nervous pathways at peripheral 
(local), segmental (in the spinal cord) and at supraspinal level within central nervous 
system (CNS).  
Starting at a peripheral level, both manual and electrical stimulation increase glucose 
uptake and microcirculation (267-270). When needles are inserted and stimulated, 
peripheral nerve terminals releases several neuropeptides, such as neuropeptide Y 
(NPY), vasoactive intestinal polypeptide (VIP), substance P and calcitonin gene-
related peptide (CGRP) an gives an immediate local reaction, by which the two latter 
is probably involved, with an increase in microcirculation (267, 271, 272). Moreover, 
data from administration of the opioid antagonist naloxone also suggest low-
frequency EA stimulated peripheral opioid release (273). 
Mechanoreceptors, responding to mechanic pressure or distortion, are activated by 
muscle contractions and are suggested to be involved in the somatic response of both 
manual and electrical stimulation (274, 275). Activation of mechanoreceptors by 
manual or electrical stimulation activates sensory nerve fibers; myelinated Aα, β, δ and 
unmyelinated C-fibers (276, 277). These signals are transmitted to the spinal cord 
(segmental level) where they through spinal reflexes may modulate the sympathetic 
output to the target organs in the same area of innervation as where there needles are 
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placed (278). Importantly, these signals are also controlled via supraspinal pathways 
within the CNS (279).  
The efficacy of acupuncture for analgesia has been extensively studied and widely 
used. The involvement of endogenous opioids within the central nervous system has 
been suggested to mediate the effect of acupuncture-induced analgesia and lowering 
of blood pressure (280-283). There are three opioid receptors μ, δ and κ found in 
peripheral afferent nerve terminals and within the central nervous system in areas 
related to nociception and pain (284, 285). β-endorphin, one of the cleavage products 
of pro-opiomelanocortin (POMC), binds to the μ-receptor with high affinity and has 
received special attention (284). β-endorphin produced in the arcuate nucleus of the 
medial basal hypothalamus is released within CNS but it is also produced in the 
pituitary where it is released into the peripheral circulation (286-288). The β-endorphin 
produced in hypothalamus project to the midbrain (especially the peri-aqueductal 
grey) and brainstem nuclei where it can influence pain sensitivity and autonomic 
function (287, 288). The effect on autonomic function include effects on the 
vasomotor centre with regulation of blood pressure and muscle sympathetic activity 
(markers of sympathetic tone) (289). The other system is also under hypothalamic 
control, by corticotrophin releasing hormone (CRH), and involves the anterior 
pituitary lobe where POMC is cleaved into equal amounts of β-endorphin, melanocyte 
stimulating hormone and adrenocorticotrophic hormone (ACTH) that is released into 
circulation (290). The two systems work independently but both can be activated by 
afferent nerve activity such as manual and low-frequency electrical stimulation of 
acupuncture needles, and exercise (287).  
The β-endorphinergic system is involved in many physiological effects, both centrally 
and peripherally, such as reproductive function, analgesia, stress response and 
carbohydrate metabolism (291). Both circulating and central levels of β-endorphin 
have been shown to be modulated by acupuncture (292-294). Further implications of 
acupuncture involving modulation of autonomic function are the reducing effect on 
muscle nerve sympathetic activity and blood pressure (295, 296). The pain reliving 
effect of acupuncture was further blocked by low doses of naloxone, an opioid 
receptor antagonist, and the blood pressure suppression by high doses of naloxone 
(296, 297). 
The connection between central β-endorphin and reproductive function involves both 
direct and indirect tonic inhibitory effects on GnRH and subsequent LH release, and 
possibly also GnRH biosynthesis (288, 298). It is generally accepted that opioids 
mediate the inhibitory effect of estrogen (299). Moreover, a reduction in opioid 
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inhibitory tone amplifies, and is essential, for generation of the LH surge preceding 
ovulation (288, 300). 
Circulating β-endorphin is considered to be more related to stress stimuli than actually 
reflecting central opioid activity and should not be used as a marker of central activity 
(301). Still, the changes in plasma β-endorphin provide a link to the HPA axis, since β-
endorphin is co-released with ACTH from the pituitary (290). The controlling factor 
CRH is released by stress, but it is also known to decrease GnRH secretion, linking it 
back to the reproductive axis (302). Acupuncture has been shown to decrease levels of 
CRH within hypothalamus and may therefore present effects on both HPO and HPA 
axis (303). 
In general the effect of acupuncture may also be influenced by the patient’s own 
expectations, since there is a strong psychological component to it (304). The use of 
placebo in acupuncture experiments are therefore always under debate, but the use of 
so called placebo needles or minimal/sham acupuncture may not be recommended 
since clinical studies suggest they are not an inert treatment (305, 306).  
Implications of acupuncture in PCOS 
Since many of the features of PCOS is associated to disturbed opioid or sympathetic 
tone, including disturbed gonadotropin secretion, insulin resistance and central obesity 
(207, 291), they may be implicated in the pathogenesis of the condition. PCOS have 
higher levels of circulating β-endorphin which may contribute to the pathogenesis, 
possibly by insufficient inhibition of central β-endorphins on GnRH secretion (291, 
307-309). This is supported by studies in which the μ-receptor antagonist naltrexone 
improves cyclicity and SHBG, reduces androgen levels, LH/FSH and LH response to 
GnRH (310-312). Naltrexone also results in improvements of metabolic parameters in 
PCOS indicating involvement of β-endorphins in insulin sensitivity (310, 312, 313). 
To study the therapeutic effects of acupuncture in PCOS may therefore be well-
established, and is persistently performed in China although those data mostly are 
inaccessible due to language barriers. 
The relation between acupuncture, β-endorphin and sympathetic activity seems to be 
sustained also in PCOS. Acupuncture treatment has been shown to reduce both high 
plasma β-endorphin and sympathetic nerve activity and increase low hand-skin 
temperature (217, 295, 314).  
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For ovulation induction, often the main outcome except for live birth when treating 
PCOS women, acupuncture has indicated beneficial effects. Case-control studies on 
acupuncture for women with PCOS as well as with undefined anovulation show 
improvements menstruation pattern, LH/FSH ratio, estrogen and testosterone with 
long lasting effects (314-316). The effect on the HPO axis was recently confirmed in 
our previous RCT in which acupuncture with combined manual and low-frequency 
(2Hz) electrical stimulation of needles was superior to exercise and no intervention in 
improving menstrual frequency and lowering circulating levels of testosterone in 
PCOS women (233).  
Clinical data demonstrating metabolic responses are scarce, and even more so in 
PCOS although experimental data demonstrate improved insulin sensitivity by 
acupuncture in rat PCOS models (317). Recent reviews support that acupuncture may 
be beneficial for both obesity and insulin sensitivity in diabetes but the included 
clinical studies are underpowered with poor methodological quality and more well-
performed RCT’s are required (318, 319). There is evidence that points toward a 
relation between circulating β-endorphin and increased pancreatic insulin and 
glucagon secretion both experimental and in healthy, diabetes and PCOS subjects 
(320-323) implicating a hypothetically metabolic response of acupuncture in PCOS. A 
hypothetical mechanism for acupuncture in PCOS is presented in figure 4. 
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Figure 4.  Schematic illustration of a hypothetical mechanism explaining the effects of acupuncture in 
PCOS. 1) Stimulation of acupuncture needles in skeletal muscle excites ergoreceptors that activate afferent 
sensory nerve fibers. These signals are transmitted to the spinal cord where they 2) through spinal reflexes 
may modulate the sympathetic output to the target organs in the same area of innervation. 3) Signals also 
reach the central nervous system via supraspinal pathways where they can exert central effects. Hypothalamic 
β-endorphin is implicated in the effect of acupuncture. It modulates the autonomic system but may also alter 
the release of GnRH and CRH. 4) These can enable an effect on reproductive function (via LH and 
FSH), adrenal function (ACTH), and pancreatic function (circulating β-endorphins). (ACTH – 
adrenocorticotrophic hormone, CNS – central nervous system, CRH – corticotrophin releasing hormone, 
EA – electro-acupuncture, FFA – free fatty acids, FSH – follicle stimulating hormone, GnRH – 
gonadotropin releasing hormone, LH – luteinizing hormone.) 
 
Animal models of PCOS 
Animal models are used to study etiology and pathophysiology, perform drug-
screening and investigate effects of treatment in ways that are not possible in humans 
as well as to perform statutory pre-clinical studies. In order to mimic the 
pathophysiology of the syndrome several models in different mammalian and primate 
species have been developed during the years, each with its advantages and 
disadvantages. The unknown etiology of PCOS problematizes the use of these animal 
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models. Add on the difficulties to agree on diagnostic criteria as well as ethical 
considerations regarding use of animals for research and we can conclude that all of 
them involve limitations. They can help us understand some of the pathogenesis 
behind PCOS but they will not give us all the answers (29). The most informative 
animal models of PCOS are perhaps the prenatally androgenized sheep and rhesus 
monkeys that has offered knowledge of the role of androgens in fetal life in 
developing metabolic and reproductive abnormalities such as insulin resistance, 
anovulation and LH hyper secretion (29-32). Advantages over similar rodent models 
are that sheep and subhuman primates such as rhesus monkeys have a follicular 
development that is completed in utero, while rodents´ are completed postnatally 
(324). Although clinical manifestations in these sheep and rhesus monkey models are 
very similar to human PCOS the limitations of transcribing the results to human 
PCOS involve the uncertainty of common origin. Moreover, the achieved 
testosterone levels in these models are a great deal higher than in pregnant women 
with PCOS (325, 326). Since human and non-human primates placentas produce 
cytochrome P450 aromatase (CYP19a1) that converts androgens to estrogens, hence 
protecting the female fetus from high androgen levels, it is not clear how much of the 
maternal androgens that actually enter the fetus (327, 328).  
Several rodent models of PCOS are currently described after exposure to androgens, 
estrogens, aromatase inhibitors and antiprogestins during intrauterine, prepubertal and 
adult life, but also from changes in light exposure and genetic mutations (39, 40, 226, 
329-336). The reproductive and metabolic effects are inconclusive and seem to be 
dependent of timing and length of exposure, substrate and dose (218, 219). The rat 
model used in this thesis is based on prepubertal long-term and continuous 
administration of DHT to female rats, to mimic the pubertal onset of PCOS 
symptoms (24, 39) . It develops PCOS traits such as irregular cycles, polycystic ovaries 
as well as the metabolic features increased body fat, increased adipocytes size and 
insulin resistance (39).  Benefits of rodent models are their short regeneration time 
and low costs. This makes it possible to study both reproductive status and 
transgenerational transfer of PCOS traits as well as long-term effects and treatment 
regimens. One must though consider the larger species differences in relation to 
humans given their rapid ovulatory cycle with multiovulatory pattern.
PRESENT INVESTIGATION 
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AIMS 
 
General aims 
The aim of this thesis was to evaluate the effect of acupuncture on ovulatory and 
neuroendocrine, as well as metabolic, dysfunction in the pathology of PCOS, and to 
search for potential molecular mechanisms mediating the effect. 
Specific aims  
Paper I  To investigate if continuous administration of DHT in female rats, starting 
before puberty, induces changes in the hypothalamic expression of AR, 
GnRH, GnRH-receptor, and CRH. To determine whether low frequency 
(2Hz) electro-acupuncture, with intensity high enough to evoke muscle 
twitches, restore estrus cyclicity and hypothalamic protein expression.  
Paper II  To test the hypothesis that giving acupuncture with combined manual and 
low-frequency electrical stimulation to women with PCOS, increases 
ovulation frequency and improves LH pulsatility and sex steroid pattern to 
greater extent compared only to the attention part of the therapy. 
Paper III To test the hypothesis that low-frequency electro-acupuncture normalizes 
insulin sensitivity in rats with DHT-induced PCOS. To further investigate 
if this effect is achieved via restored molecular signaling related to insulin 
sensitivity and effects on lipid profile. 
Paper IV To test the hypothesis that manual- and low-frequency electrical 
stimulation of acupuncture needles improves whole-body insulin sensitivity 
in rats with DHT-induced PCOS, with electrical stimulation being more 
effective. To further investigate if the two treatment modalities have 
different effects on gene- and protein expression related to insulin 
sensitivity. 
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METHODOLOGICAL CONSIDERATIONS 
 
he papers of this thesis are based on experimental data from three 
animal studies and one clinical study, where all four focus on PCOS 
and the effect of acupuncture. Experimental methods used have 
involved acupuncture treatment procedures, cyclicity- , insulin sensitivity-  and 
body composition measurements, gene- and protein expression assessments 
and many, many biochemical analyses of blood samples. 
Ethics 
All experiments presented in this thesis have been approved by the Animal Ethics 
Committee (No. 23-2008 and 161-2010 [Paper I, III and IV]), or the regional ethical 
review board (No. 679-08 [Paper II]) of the University of Gothenburg, according to 
Swedish law. Care of animals was in agreement with the principles of the Guide to the 
Care and Use of Experimental Animals (www.sjv.se) and the human study was 
performed in accordance with the Declaration of Helsinki.  
 
Animal studies 
Animals used were Wistar rats from Charles River (Germany). They were housed at 
the Experimental Biomedicine facility, Sahlgrenska Academy, University of 
Gothenburg and kept under controlled conditions with 21–22°C, 55–65% humidity 
and a 12-h light, 12-h dark cycle. Rats were fed commercial chow and tap water ad 
libitum. 
 Animal model and study designs 
Study designs of experiments of the animal experiments are presented in figure 5. The 
PCOS animal model used in studies I, III and IV was induced by subcutaneous 
implantation of 90-d continuous-releasing pellets containing 7.5 mg DHT (daily dose 
of 83 μg) into female rats. The pellets were implanted pre-pubertally (day 21) to mimic 
T 
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the clinical manifestation of human PCOS around puberty/adolescence (24) and the 
dose was chosen to simulate the approximate 1.7 fold higher plasma DHT levels seen 
in PCOS women versus controls (337, 338). This dose has later been demonstrated to 
increase DHT in rats to supraphysiological levels, several fold higher than in control 
animals (253±21 pg/ml, vs. 31±3 pg/ml in controls), measured with 
radioimmunoassay (RIA) (339). However, the serum DHT levels in PCOS women 
might be underestimated and may not represent the actual concentration and 
androgenic bioactivity in the local tissues where DHT is converted from testosterone. 
The model display both the ovarian and metabolic characteristic of PCOS such as 
irregular cycles, polycystic ovaries, insulin resistance and obesity (39).  
Figure 5. Study designs on time axes for experiment of A) paper III and B) paper IV. Pellets were 
implanted at wk 3 (21 d of age) while treatment began at wk 10 of age (7 wk after implantation of 
pellet). A) In paper III animals were divided in control (placebo pellet), untreated PCOS (DHT pellet) 
or PCOS receiving electro-acupuncture. Blood sampling was performed at wk 13 of age and the 
experiment was concluded with the clamp. B) In paper IV all rats received the DHT pellet and were 
either left untreated (control) or received manual acupuncture (PCOS MAN) or electro-acupuncture 
(PCOS EA).  Rats that were not treated in the two experiments were still handled the same amount of 
time. DHT -  dihydrotestosterone, wk – week, DEXA – dual-energy X-ray absorptiometry, EA – 
electro-acupuncture). 
  
A
B
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The experimental studies presented here were based on previous  reports  where we 
demonstrated that repeated acupuncture with low frequency (2Hz) electrical 
stimulation in female rats with DHT-induced PCOS increased low insulin sensitivity 
as well as improved cyclicity pattern and ovarian morphology (340). The aim of the 
present thesis was to elucidate the effect and mechanistic action of repeated 
acupuncture treatment. To be able to compare the results with previous studies, the 
same DHT-induced PCOS model was chosen with the same dose of DHT.  
Treatment 
The acupuncture with electrical stimulation treatment in paper I, III and IV was 
performed as previously described but with daily treatments (5 days per week) instead 
of three treatments per week (317). In brief, needles were inserted under light 
anesthesia in rectus abdominis and in triceps surae muscles, both bilaterally, in the 
somatic segments corresponding to innervations of the ovaries (T10-L2 and at sacral 
level). Animals were then awake during treatment session and needles were connected 
to an electrical stimulator and stimulated with low frequency (2 Hz) burst frequency. 
The intensity of stimulation was adjusted during each session to visible, non painful 
muscle contractions. To accustom the animals, length of each treatment was gradually 
increased from 15 min in the first week to 25 min the final week. Although animals 
were placed in fabric harnesses and suspended over the bench, they sometimes 
escaped the treatment. Animals were then re-anaesthetized and re-attached, but to a 
maximum of two times per day to avoid stress and excessive isoflurane impact. Rats 
were then treated as usual the following day, but were not excluded from the 
experiment. This escaping behavior was more frequent in the beginning of the 
treatment period but was not considered a problem in the end when the animals were 
used to treatment. 
 
Clinical study 
The clinical study described in paper II was conducted at the Sahlgrenska University 
Hospital, and at the Sahlgrenska Academy at University of Gothenburg, Sweden 
(341). It was registered at ClinicalTrials.gov: identifier NTC00921492 and is reported 
according to the CONSORT and STRICTA guidelines (342, 343). 
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Included subjects 
PCOS patients were recruited by advertisement in local newspapers. Women were 
diagnosed according to the Rotterdam criteria and underwent two-dimensional 
transvaginal ultrasonography to examine ovarian morphology, and clinical 
examination of hyperandrogenism and menstrual frequency pattern. All participants 
gave informed oral and written consent before inclusion. 
Inclusion criteria; fulfill two out of three: 
 Polycystic ovaries (≥12 follicles 2–9 mm and/or ovarian volume 
≥10 ml in one or both ovaries). 
and/or 
  Oligo/amenorrhea (oligoamenorrhea: intermenstrual interval > 35 
days, less than six menstrual bleedings in the past year.  
and/or  
 Clinical signs of hyperandrogenism (hirsutism or acne). [Ferriman-
Gallwey (FG) score ≥8 (344)ǀ Do you have excessive acne? (Yes/no)]. 
 
Exclusion criteria 
 <18 or >38 years of age.  
 Body mass index (BMI) >30. 
 Any pharmacological treatment within the last 3 months.  
 Breastfeeding or received acupuncture within the last 24 weeks. 
 Cardiovascular disease (CVD), diabetes mellitus, other endocrine 
disorders (e.g., congenital adrenal hyperplasia, Cushing´s syndrome 
or androgen-secreting tumors).  
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Study design 
The study design of the clinical study in paper II is presented in figure 6. Throughout 
the inclusion period patients were instructed to document menstrual bleeding with the 
aim to perform baseline assessments at day 8-12 in the cycle, and weekly progesterone 
measurements were performed to confirm ovulation. Computer-generated 
randomization to refer subjects to either acupuncture or attention control treatment 
was performed after baseline assessments to avoid influence by expectation of 
treatment. After the 10-13 weeks intervention period, with treatment twice per week, 
baseline assessments were repeated. Weekly progesterone measurements were 
performed throughout the intervention period.  
 
Figure 6. Study design on time axis for paper II. Randomization and allocation to either acupuncture or 
attention control intervention was performed immediately after baseline measurements. The treatment period, 
with weekly progesterone measurement to establish ovulation, lasted for 10-13 weeks and was concluded by 
repeating the baseline measurements. 
 
Interventions 
Both groups visited the same team of two physical therapists twice weekly, for 30 
minutes per visit. Women were allowed to rest and listen to relaxing music during 
intervention. Women receiving acupuncture alternated between two sets of protocols 
to avoid soreness due to frequent treatments. The protocols were based on previous 
clinical (233) and experimental (279) studies, as well as clinical experience and are 
presented in Table 2.  
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Table 2. Used set of acupuncture points. 
CV: conception vessel; EA: electro-acupuncture; GV: governor vessel; LI: large intestine; 
LR: liver; M: muscle; Mm: muscles; PC: pericardium; SP: spleen; ST: stomach. 
 
Needles were placed in abdominal and leg muscles in the innervation area 
corresponding to sympathetic innervation of the ovaries and uterus. In addition, 
needles were placed in the hands. After insertion all needles were immediately 
stimulated manually by rotations to evoke de qi sensation. Thereafter needles in 
abdominal and leg muscles were stimulated electrically with low-frequency (2 Hz) 
burst frequency to induce muscle contractions, while remaining needles were 
stimulated manually, totally 4 times during treatment. To control for the attention 
involved in the treatment procedure, women in the attention control group were 
visited by the therapist, who ensured well-being, every 10 minutes during each stay. 
To avoid group differences in expectation of intervention, participants were 
thoroughly informed that it is not known whether the active component of the 
Points Location Stimulation Innervation Muscle location 
  Set 1     
CV3 
Midline EA, 2Hz 
L1 
Fibrous tissue, linea alba 
CV6 Th11 
ST29 Bilateral EA, 2Hz Th6-12 M. rectus abdominis 
SP6 
Bilateral EA, 2Hz 
L4-5, S1-2 Mm. flexor digitorum longus, tibialis posterior 
SP9 S1-2 M. gastrocnemius 
LI4 Bilateral Manual C8, Th1 
Mm. interosseus dorsalis I, 
lumbricalis II, adductor 
pollicis 
GV20 Midline Manual C2-3 Aponeurosis epicranii 
     
  Set 2     
CV3 
Midline Manual 
L1 
Fibrous tissue, linea alba 
CV6 Th11 
ST25 
Bilateral EA, 2Hz Th6-12 M. rectus abdominis 
ST29 
SP6 
Bilateral EA, 2Hz 
L4-5, S1-2 Mm. flexor digitorum longus, tibialis posterior 
LR3 S2-3 M. interosseus dorsalis I 
PC6 Bilateral Manual C8, Th1 M. flexor digitorum superficialis 
GV20 Midline Manual C2-3 Aponeurosis epicranii 
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current intervention is acupuncture per se, and/or the attention of the therapist 
handling the needles. Women were also encouraged not to discuss the intervention 
with each other.  
Sampling and outcome measures 
During inclusion visit, patients underwent a trans-vaginal two-dimensional 
ultrasonography of the ovaries, measuring ovarian volume and number of antral 
follicles ≤ 9mm, as well as endometrial thickness. At the day of baseline assessments 
patients arrived after at least 4 hours of fasting (including food, coffee/tea/smoking). 
Anthropometric analyzes were performed before a standardized meal was provided. 
An intravenous venflon cannula was inserted 1 h before start of blood sampling to 
avoid stress interference. Blood sampling for LH and cortisol analyses were 
performed every 10 min for 12 h throughout the night. Blood sampling for FSH and 
sex steroid analyses were performed with 60 and 240 min intervals respectively. 
Encountered problems with blood sampling included difficulties with insertion and 
clotting of the venflon cannula. This could delay start of blood sampling or result in 
missing samples. Sleep quality during the night varied between subjects and should 
have been recorded and related to cortisol levels.  
Estrous cyclicity and ovulation frequency 
Estrous cyclicity (paper I, III-IV) 
The estrous cycle in a rat is four days long and is divided into proestrus, estrus, 
metestrus and diestrus. Ovulation occurs between the beginning of proestrus and the 
end of estrus. Each stage is determined by the proportion of cell types present in the 
vaginal smears, i.e. epithelial cells, cornified cells and leukocytes. In proestrus the 
predominant cell type in the smear is nucleated epithelial cells; in estrus it is anucleated 
cornified cells; in metestrus it consists of similar proportions of leukocytes, cornified, 
and nucleated epithelial cells; and in diestrus the predominant cell type is leukocytes 
(Figure 7) (345). In paper I, III and IV analysis of vaginal smears were performed 
daily, from start of acupuncture treatment and throughout the study, to monitor the 
effect of acupuncture on the estrous cycle of the rats. Cycle stage was also determined 
to enable euthanization of cycling rats in the same stage of the cycle for correct 
comparison. Several physiological parameters, for example insulin sensitivity, are 
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known to fluctuate during the cycle in both rats and humans due to the impact of sex 
steroids. In the presented studies we performed clamp experiments and sacrificed 
animals during estrus. Since DHT rats are acyclic or have irregular cycles and display 
presence of leukocytes in their vaginal smears, indicating a pseudo diestrus (Figure 7) 
(39, 340), one may argue that a more correct comparison between groups would have 
been accomplished in diestrus stage. In rats, insulin sensitivity is at the lowest during 
estrus phase when estrogen is low and progesterone high (346, 347). Our rationale for 
choosing estrus is because of the low and relatively stable estradiol levels together with 
low insulin sensitivity (the main outcome measurement). This would ensure that 
potential differences in insulin sensitivity between groups were true, since PCOS rats 
were compared with control rats in their stage of lowest insulin sensitivity. 
Figure 7. Vaginal smears indicating different stages of estrous cyclicity of the rat including diestrus, 
proestrus, estrus and metestrus. Pseudo diestrus of DHT-induced PCOS rats. Modified from previously 
published picture in Feng Y et al. (2009). Hypothalamic neuroendocrine functions in rats with 
dihydrotestosterone-induced polycystic ovary syndrome: effects of low-frequency electro-acupuncture. PLoS 
One 4:e6638 (348). 
Ovulation frequency (paper II) 
Progesterone is produced and secreted from corpus luteum to prepare the 
endometrium for implantation of an embryo. Circulating levels can therefore be used 
as a marker of ovulation. In our previous studies self reported menstrual frequency 
was recorded, but since anovulatory cycles occur, this measure alone cannot be 
regarded as reliable (349). Measuring progesterone is hence a more trustworthy option 
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to confirm ovulation. This was made in study II where weekly measurements were 
performed during the intervention and differences in ovulation frequency between the 
study groups were evaluated. Since we are missing pre-intervention ovulation data we 
were unable to elucidate whether ovulation increased although most subjects were 
anovulatory.  
 
Assessment of body composition 
Body composition (paper II) 
To evaluate body composition in study II we measured body height, body weight, 
waist and hip circumference and sagittal diameter and calculated body mass index 
(BMI)[body weight (kg) / body height2 (m2)] and waist-hip-ratio (WHR)[ waist 
circumference/hip circumference]. These measures give a crude estimation of body 
composition with regard to adiposity and adipose tissue distribution but no 
information about amount of fat mass or ratio of subcutaneous vs. abdominal visceral 
fat. Weight and BMI is principally dependent on both fat and muscle content, while it 
is only the excess fat that leads to co-morbidities such as type 2 diabetes and 
cardiovascular disease. To identify fat percentage a foot-to-foot bioelectrical 
impedance system (Tanita, Middlesex, United Kingdom) was used. This technique is 
based on resistance of electrical currents. Lean tissue has a higher electrolyte and water 
content than fat mass, hence a better conductor of electrical signals. By inducing a low 
energy, high frequency signal through an anterior electrode and measuring the voltage 
drop (resistance) at the posterior electrode, a measurement of total body water, lean 
mass and fat mass can be obtained. It is highly correlated to waist circumference and 
BMI and the traditional hand-to foot bioelectrical impedance system (350) but may 
underestimate body fat percent compared to MRI (351). For more accurate 
measurements the gold-standard technique magnetic resonance imaging (MRI) is a 
more distinguished method, which allows area and volume determinations of specific 
tissue compartments with high precision and reproducibility, with the disadvantage of 
being much a more expensive and resource-demanding resource. 
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Dual-energy X-ray absorptiometry (paper III) 
In paper III, dual-energy X-ray absorptiometry (DEXA) was used to assess body 
composition in anaesthetized rats. Obtained information from DEXA includes bone 
mineral content, body fat and lean tissue mass. These three compartments absorb 
energy from an X-ray beam based on two different energy levels in a tissue-specific 
manner. Radiation dose is very low and it is easy to use with low operational costs, 
making it attractive in clinic. One must keep in mind though that the obtained body 
fat represents total body fat mass and not total adipose tissue mass (352). It can 
neither distinguish different fat depots from each other such as MRI can. 
 
Insulin sensitivity tests 
Estimating insulin sensitivity may be of importance for many physiological conditions 
or when evaluating pharmaceutical effects. There are several different methods 
available and the choice of method can be based on the required accuracy. Methods 
used in the papers comprising this thesis are the euglycemic-hyperinsulinemic clamp, 
different insulin sensitivity indexes and the oral glucose tolerance test. 
Euglycemic-hyperinsulinemic clamp (paper III) 
Whole body insulin sensitivity is commonly measured in clinic for different conditions 
such as type 2 diabetes, metabolic syndrome, obesity, PCOS and during pregnancy. 
The golden standard procedure for measuring insulin sensitivity is the euglycemic-
hyperinsulinemic clamp technique. It is an invasive procedure measuring the amount 
of glucose needed to compensate for an increased level of insulin, to avoid 
hypoglycemia and ensuring glucose levels within a euglycemic range. Insulin is infused 
at a fixed and predetermined dosage with the aim to raise plasma levels to a higher and 
stable plateau. Without exogenous infusion of glucose, hypoglycemia would develop 
rapidly. Addition of a variable glucose infusion with the purpose of keeping glucose 
levels “clamped” at a predetermined euglycemic level will provide information 
regarding the amount of glucose that is metabolized per kilo body weight at that fixed 
insulin level. In summary, the method involves one fixed and predetermined insulin 
infusion and one variable glucose infusion (353). The clamp technique assumes that 
basal hepatic glucose production is suppressed when infusing insulin and glucose. In 
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normal subjects this is true, but in different states of insulin resistance where 
suppression of glucose production might be impaired, risking that the amount of 
glucose that is metabolized is underestimated. The degree of insulin resistance is 
inversely proportional with the peripheral glucose uptake and is termed glucose 
infusion rate (GIR) or glucose disposal rate (GDR) and is normalized to body weight 
(mg/kg x min).   
In paper III rats underwent the clamp during anesthesia. They were infused with a 
high bolus dose of human insulin to shut down endogenous insulin and glucose 
production, followed by a stable lower insulin infusion. Glucose was then 
administered continuously to achieve a steady state at a euglycemic level. Since most 
glucose uptake occurs in muscle and not in adipose tissue, and overestimation of 
insulin resistance may be the case in our obese rats. GIR could in that case have been 
normalized to lean mass. When computing this, significance between groups remains. 
Insulin sensitivity indexes (paper II) 
Due to the inherent complexity, the clamp is mainly used in medical research, while 
other simpler and cheaper techniques and indexes have been developed for clinical 
use. Alternative methods are glucose tolerance tests or indexes based on fasting 
glucose and insulin levels such as homeostasis model assessment (HOMA) (354) and 
quantitative insulin sensitivity check index (QUICKI) (355). These indexes correlate 
rather well with the clamp in healthy controls, type 2 diabetes and PCOS and are 
routinely used (356). In paper II HOMA index was calculated from the final blood 
samples obtained in the morning after the blood sampling for LH pulsatility. The 
clamp was not performed since assessment of insulin sensitivity was not a primary aim 
of the paper.  
Oral glucose tolerance tests (paper IV) 
A glucose tolerance test (GTT) gives a measure of how quickly an administered dose 
of glucose is taken up and cleared from the blood. It is widely used in clinic for 
diagnosis of type 2 diabetes and glucose intolerance where fasting- and 2h post-
glucose is used for diagnosis. Experimentally, glucose and insulin areas under the 
curve (AUC) as well as glucose and insulin levels during different time points are also 
used to assess insulin sensitivity. The glucose can be administered through different 
routes and doses, but most common is the orally administered glucose tolerance test 
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(OGTT). In paper IV blood glucose was measured after a 5-h fasting and rats were 
thereafter given a physiological dose of glucose (2 g/kg) orally by gavage. Blood was 
collected from the tail after 15, 30, 60 and 120 min and glucose levels were analyzed 
directly.  Plasma samples were collected at 0, 15 and 30 min for insulin analysis by 
ELISA. Rats were conscious throughout the experiment.  
Compared to the clamp, an OGTT provides more information about glucose 
tolerance than insulin sensitivity, but it is also a more physiological test including 
glucose uptake and insulin release. In paper IV we did not want an insulin load on the 
muscle and fat tissues possibly affecting later gene- and protein analyses which would 
have been the case if we finalized with a clamp. Instead, when using the OGTT it was 
possible to perform the experiment one week before sacrificing the animals and was 
therefore more suitable. Different indexes obtained from the OGTT, such as the 
insulin sensitivity index described by Matsuda (357) used in paper IV, has also been 
shown to correlate rather well with clamp data (358). For even more information 
regarding insulin sensitivity, an additional insulin tolerance test to investigate the 
lowering effect on blood glucose could have been made. 
 
Gene expression  
Studying gene expression is a powerful tool in life science research. It can answer 
questions like; in which tissues or species different genes are active, the level of 
expression, when they are activated, in validation of transgenic organisms/cells or to 
measure viral/bacterial load, cancer and resistance development. Techniques includes 
traditional polymerase chain reaction (PCR) developed in the 1980’s, the related real-
time PCR and the newer and more refined high-throughput micro-array and RNA-seq 
techniques. Measuring mRNA levels is one way to indirectly estimate the protein 
levels within a cell or tissue. It is easier than measuring proteins directly but one must 
keep in mind that the two can’t be completely correlated and it is the protein levels per 
se that control cellular processes and events. A change in the protein coding transcript 
must not imply a change in protein levels but it gives an indication and can be 
hypothesis generating. 
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Real-time RT-PCR (paper IV) 
Real-time reverse transcriptase (RT) PCR is based on the PCR technique, but with 
mRNA instead of DNA as starting material. As a first step the enzyme reverse 
transcriptase is used to create complementary DNA is therefore required. Real-time 
then simply refer to that the DNA amplification is monitored after each amplification 
cycle instead of after e.g. 40 cycles. This is to enable estimation of the original amount 
mRNA and not risk that reaction components in concentrated samples will be used 
up before final analyzes. This is monitored by the addition of a fluorogenic probe that 
links a change in fluorescence with amplification of DNA and then detects the 
emitted light. The intensity of the emitted light is related to the amount of amplified 
DNA (359).  
In paper IV we used TaqMan®low density array (LDA) cards (Applied Biosystems, 
Foster City, USA). These are micro fluidic cards with 8 sample-loading ports each 
connected to 48 reaction wells containing primers and probes for selected gene assays. 
The probe in TaqMan assays consists of a sequence complementary to the target 
sequence with a reporter dye at the 5’ end and a quencher at the 3’ end. As long as the 
probe is intact the emission from the reporter dye is quenched. During each 
amplification cycle DNA polymerase cleaves the probe and releases the reporter dye 
which then can emit fluorescent light. Each cycle increases the emitted light and is 
monitored in real-time.  A predetermined threshold is used and the cycle where this 
threshold is reached is called the cycle threshold, CT. The format allows for analyzes 
of up to 384 (48x8) different genes but we designed cards with 48 genes with the 
possibility to load 8 different samples. These genes also included 5 putative reference 
genes. For quantification of the real-time RT-PCR result two different methods can 
be used, either the standard curve method with absolute quantification or the 2-∆∆CT 
method with relative quantification. We used the 2-∆∆CT method for relative 
comparison between samples (360). In short, the first step was to normalize all genes 
to a reference gene to compensate for experimental variation, giving the ∆CT value. 
An optimal reference gene is stable between tissues and individuals and should not be 
altered by the experimental setup or design. We used the Normfinder algorithm to 
find the most stable gene or gene combinations with the lowest intra- and intergroup 
variability (361). To convert ∆CT to relative quantities we normalized it to the mean of 
the untreated group giving ∆∆CT. Finally we transformed it to fold changes 2-∆∆CT 
with the untreated control group representing mean of 1 and relative numbers for the 
different treatment groups.  
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The first steps including mRNA isolation and cDNA preparation are technically 
challenging and measures must be taken to assure DNA-free, good quality and non-
degraded RNA, suitable primers and probes and so on, but correctly used it is 
considered to be the most sensitive method for quantification of mRNA levels (362). 
Due to the format of the cards, the same mix of enzymes and cDNA is used for all 
measured genes, which diminishes pipetting errors, making the method easy to use 
and very accurate. For further investigation and quantification of your target protein, 
Western blot may be recommended. 
 
 Protein expression 
Measuring the amount of protein within a tissue, organ or cell type is widely used and 
is more descriptive and informative than only looking at gene expression. Looking at 
the protein level gives you a snapshot of the actual processes that is taking place 
within the cell at that precise moment. The actual activity of proteins may be 
dependent to post-translational modifications such as phosphorylations, something 
gene expression does not consider, but possible to analyze in protein expression 
methods.  However, measuring protein expression are at present time much more 
time consuming and cumbersome than gene expression. For larger screenings of 
several targets, gene expression may be used but further confirmation with protein 
expression is warranted. Protein expression methods are based on the use of 
antibodies, either polyclonal or monoclonal. Polyclonal antibodies recognizes several 
different epitopes on a target molecule but can be less specific and cause problems 
with background staining or false positives. Monoclonal antibodies are instead 
specifically directed to only one epitope on the target molecule, but are sometimes too 
specific. They are also more technically demanding and expensive to produce. 
 Immunohistochemistry (paper I, III-IV) 
Immunohistochemistry (IHC) is used to demonstrate the presence or the localization 
of a target antigen within a tissue. The antigen is recognized by directed antibodies 
that are both directly or indirectly coupled to different detection molecules, and 
thereafter visualized in a microscope. It is now a standard assay in pathology although 
lack of standardization and reproducibility. Quantification of IHC data has been a 
challenge and lacked a broad acceptance although new systems and software has been 
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developed (363). One fair interpretation may be that it is semi-quantitative. Different 
detection methods can be used and most commonly used are colorimetric, and direct 
or indirect immunofluorescence. Colorimetric/chromogenic methods such as 3,3'-
Diaminobenzidine (DAB) staining is commonly used where an enzyme convert DAB 
into brown colour products. It is sensitive, with a long shelf-life for stained sections 
but can cause background staining and signal amplification. Immunofluorescence 
using antibodies coupled to fluorochromes and visualizing in confocal microscope is 
considered to be more sensitive and specific, with easier interpretation and ability for 
simultaneous visualization of different targets in e.g. co-localization experiments. 
Background emission and short time-frames are some of the drawbacks of 
fluorescence. In paper I DAB staining was used for quantification (cell count of 
immunoreactive cells) while dual-immunofluorescence staining was used for co-
localization experiments. In paper III and IV we used immunofluorescence staining 
for semi-quantification and protein localization. 
Western Blot (paper I, III-IV) 
Western Blot, first described by Towbin et al. in 1979, is a widely accepted technique 
to analyze protein content within tissues or cells (364). The method is based on 
protein separation by size by gel electrophoresis and thereafter protein transfer by 
electroblotting to a nitrocellulose or polyvinylidene difluoride (PVDF) membrane. 
Antibody detection is lastly used for detection of the target protein. Detection 
methods include colorimetric, chemiluminescent, fluorescent and radioactive probes 
or substrates. One advantage of PVDF membranes are their inherent resistance to 
damage and their ability to easier be stripped and re-probed with new antibodies 
without causing background noise. The main benefit of using western blot is the 
control of antibody specificity. This is possible since the size of the detected protein 
band can be compared with the expected protein size and you can also evaluate 
whether the antibody binds to more than one protein, and if you have degradation 
products. This information is not included in immunohistochemistry, and by this you 
can presume that you analyze the correct protein. Western blot is also considered to 
be more quantitative compared to IHC. For further quantification other methods like 
ELISA, radioimmunoassay (RIA) or enzyme immunoassay (EIA) may be used. 
However, in these methods the size of the immunoreactive protein cannot be 
controlled and the concentration could be underestimated since the antibodies might 
only recognize correctly folded protein.  
64 Julia Johansson |  
 
Compared to working with DNA and RNA, working with proteins involves 
challenges due to their very different inherent properties. The specificity and 
sensitivity of a western blot is also mainly due to the chosen antibodies. Conditioning 
optimization for each protein and antibody is therefore required, and due to the 
amount of different steps in western blot this can be very time consuming. In paper I, 
III and IV western blot with chemiluminescent detection was used for protein 
quantification. We encountered problems like unspecific antibodies, no visible protein 
bands and high background staining. These were solved by testing different antibodies 
(both primary and secondary), blocking solutions (skim milk or bovine serum 
albumin, BSA), concentrations and incubation or washing times. 
 
Hormone pulsatility analyses (paper II) 
Several of our hormones and gonadal sex steroids are secreted pulsatile where several 
regulatory inputs control and generate these pulses. A pulse is defined as a punctuated 
time delimited event with a marked chronological increase and decrease in the 
secretion rate. Both the frequency and amplitude can determine the mean 
concentrations and can be altered in physiological conditions (365). There are now 
several software’s available to calculate the characteristics of pulsatile secretion 
including Pulse XP and other Matlab algorithms. 
In paper II identification and characterization of LH and cortisol pulsatility and 
secretion pattern were made with Pulse XP software using Autodecon and ApEn 
applications. AutoDecon is a validated, non-subjective and standardized algorithm for 
the detection of hormone secretion pulses. Compared to previous versions it is 
completely automated and does not require estimated input such as number of peaks, 
positions and amplitudes (366, 367). AutoDecon uses a deconvolution algorithm 
which means that it separates a hormone concentration time series into the two 
events: the rate of hormone entry and the rate of hormone removal from the 
bloodstream. A fitting module within the program fits a mathematical model to your 
experimental data with a weighted nonlinear least-squares algorithm so the parameters 
of the model have the highest probability of being correct. An insertion module then 
adds a presumed peak at the most probable location. The triage module then performs 
a statistical test whether the presumed peak should be removed or not. This is iterated 
until no more secretion events are added or removed (367). Some of the time series 
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contained missing samples due to e.g. clotting of venflon cannula. For more than two 
consecutive missing samples files needed to be truncated before analysis, hence 
creating time series of less than 12 h. Since some of the variables were characterized as 
per 12h they needed to be re-calculated for correct comparison before statistical tests. 
Approximate entropy (ApEn) is a statistical method for the evaluation of dominant 
and subordinate patterns and temporal irregularity of serial data. These patterns do 
not have to be peak occurrences or amplitudes. It measures the logarithmic likelihood 
that m contiguous observations that are similar (within distance r) remain close (within 
r) the next incremental comparison.  Monte Carlo simulations of shuffled series are 
then analyzed to represent a maximal entropy or randomness to which your data 
could be compared. Larger ApEn mean represent greater randomness or less 
orderliness while smaller numbers represent more recognizable patterns (368). In 
paper II we used a window length of m=1 and a tolerance parameter of r = 20% 
(ApEn: 1, 20%). To calculate standard deviation of approximate entropy in each series 
1000 Monte Carlo simulations were used.  
 
Mass spectrometry (paper II) 
In paper II levels of sex steroids, androgen precursors and glucuronidated androgen 
metabolites were analyzed with gas chromatography-tandem mass spectrometry (GC-
MS/MS) and ultra performance liquid chromatography-tandem mass spectrometry 
(UPLC-MS/MS). The first part, gas or liquid chromatography, carries the injected 
mixture in a mobile phase through a heated column containing a solid phase and 
separates it into pure chemicals. The second part, mass spectrometry, identifies and 
quantifies these chemicals. As the names suggests in GC the mobile phase is a carrier 
gas and in UPLC it’s a liquid. The benefits compared to immunoassays of using a 
mass spectrometer as detector are the acquiring of both qualitative and quantitative 
data. Although the machinery has a high initial cost the specificity and sensitivity as 
well as the utility with a mass spectrometer is inferior to immunoassays. To measure 
for example low testosterone levels in females an immunoassay is simply not sensitive 
enough (369). The use of tandem mass spectrometers basically improves selectivity 
and sensitivity of the analysis.   
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Statistics 
All statistical analyses were done using SPSS statistical software (SPS inc., Chicago, 
USA). In paper I, III and IV data is expressed as mean ± standard error of mean 
(SEM) and in paper II as mean ± standard deviation (SD). P < 0.05 was considered 
significant. 
Weight development in paper III and IV was measured by mixed between-within 
analysis of variance (ANOVA) since weight was considered to be normally 
distributed. In paper III we wanted to investigate when weight started to differ 
between a healthy control group and DHT-induced PCOS rats. Therefore, t-tests 
comparing each time point were also conducted. Other comparisons between 
individual groups in paper III and IV were done by Mann-Whitney U-tests. 
In paper I multiple comparisons between groups were done with one-way ANOVA 
followed by correction of P-values by Dunnett’s post-hoc tests. 
In paper II data was analyzed according to the intention-to-treat (ITT) principle. 
Missing end of treatment data due to dropouts after baseline assessments were 
replaced using the baseline observation carried forward method. Dropouts occurring 
before baseline values were collected were excluded from the ITT analyses. All 
comparisons between the intervention groups were made by Mann-Whitney U-tests 
since most of the variables were not normally distributed. Differences in the 
categorical variables acne and menstrual cycle pattern were assessed by the chi-square 
(or χ2) test. 
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KEY RESULTS AND DISCUSSION 
 
ll results can be read in their complete in each paper included in the 
thesis. Here I take the opportunity to highlight and discuss the key 
results. To retrospect to the aims of this thesis, the results will first be 
presented and discussed in two parts concerning the mechanistic effects of 
acupuncture on 1) ovulatory and neuroendocrine dysfunction and 2) metabolic 
dysfunction. 
 
Effect on ovulatory and neuroendocrine function (paper I-II) 
Two of the key characteristics of PCOS are their hyperandrogenemia and ovulatory 
dysfunction, where the two are mutually interfering with each other to enhance the 
pathology (222). We have previously demonstrated that electro-acupuncture improves 
ovarian morphology in the DHT-induced rat PCOS model and improves menstrual 
pattern in women with PCOS (233, 370). Here we aimed to investigate whether this 
also applied for ovulation and if this effect worked through mechanisms related to the 
HPO axis.  
Acupuncture improves reproductive ovarian function 
Previous experiments have demonstrated improved ovarian morphology after electro-
acupuncture in DHT-induced PCOS rats (340). Here, in the same PCOS model, we 
followed estrous cyclicity during acupuncture treatment by daily vaginal smears. In the 
rats who received electro-acupuncture we found a re-emerging cyclicity from the 
constant pseudo-diestrus they otherwise display (39). This was later confirmed in a 
succeeding study where both electrical and manual stimulation improved cyclicity in 
DHT-induced PCOS rats, with no significant difference between the two stimulation 
modalities. Both electrical and manual stimulation of the acupuncture needles also 
increased progesterone levels, consistent with the improved cyclicity (371). In the 
clinical situation we determined ovulation frequency in PCOS women, during a 3 
month long acupuncture or attention control treatment period, by weekly 
A 
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progesterone measurement and menstrual bleeding registrations. The group who were 
allocated to acupuncture treatment had higher ovulation frequency compared with the 
attention control group, an effect that was augmented compared to previous clinical 
studies on PCOS with fewer acupuncture treatments (233, 370, 372). In addition, the 
attention control group had also high ovulation frequency, comparable with ovulation 
frequency during clomiphene citrate stimulation, as well as a previous acupuncture 
study in PCOS women (256, 372). The parallel effect on ovulation in the rat and 
human studies strengthens the results by their translational nature. No major changes 
was observed in ovarian morphology in the clinical study when counting antral 
follicles ≤ 9mm or ovarian volume, however a tendency to reduced number of antral 
follicle and ovarian volume was observed in the acupuncture group. This is in line 
with our previous animal studies where electro-acupuncture improved ovarian 
morphology in DHT-induced PCOS rats (340). In addition, in the clinical trial we 
found reduced circulating levels of inhibin B in the acupuncture group, which may 
represent decreased size of the follicular pool or explain the prevented follicular arrest 
and reduced levels of ovarian sex steroids (126-128, 131). 
Moreover, delta changes of most circulating sex steroids (E1, E2, E1-S, T, free-T, 
DHT, sex steroid precursors (DHEA, DHEA-S) and glucuronidated androgen 
metabolites (ADT-G, AD3G and AD17G), as determined by mass spectrometry 
differed between the intervention groups. Differences in E1-S, E2, DHEA, free-T 
and ADT-G held for bonferroni correction. Acupuncture reduced levels of E1, E1-S, 
E2, DHEA, DHEA-S, 4-DIONE, T, and free T from baseline to end of 
treatment. This is in line with, and extends, the previous RCT where some of these 
steroids were reduced (233). Our succeeding experimental data on the DHT-induced 
rat PCOS model have later confirmed reduced levels of testosterone after electrical 
stimulation of the acupuncture needles (371). As in previous studies we found no 
differences in SHGB levels, which could be explained by that we concurrently saw no 
treatment effect on insulin levels (51, 233). The enhanced effect regarding both 
ovulation and sex steroids may be explained by increased number of treatments, as 
our animal studies infer dose-responsive effects (317, 373).   
Acupuncture partly improves neuroendocrine function 
To further elucidate the underlying mechanisms of electro-acupuncture on the effect 
on estrous cyclicity in the DHT-induced rat PCOS model the levels and distribution 
of AR and GnRH were determined. In women with PCOS we aimed to elucidate 
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whether the effect of acupuncture is mainly of peripheral, ovarian origin or via central 
control mechanisms. To elucidate possible explanations for the effect of acupuncture 
on ovulation in PCOS women we measured LH pulsatility and secretion by a 12 h 
blood sampling procedure. 
Altered hypothalamic protein expression in DHT-induced PCOS rats 
In the rat, the highest density of GnRH neurons is located in the rostral medium 
septum (MS), diagonal band of Broca and medial preoptic area (MPO) (56). Most 
GnRH neurons send projections via mediobasal hypothalamus down to the median 
eminence where GnRH is released in to hypophyseal portal blood (374, 375). In our 
study, we found more GnRH-immunoreactive (GnRH-ir) cells in the MPO and 
horizontal limb of the diagonal band (HDB) in the PCOS rats. Additionally, 
compared to controls the PCOS rats displayed increased levels of hypothalamic 
functionally active AR and AR-ir cells in the MPO as determined by western blot and 
IHC. This implies that androgens have a regulatory effect on the GnRH neurons. 
Moreover, the increased levels of GnRH-ir cells and AR in hypothalamus were 
reduced after electro-acupuncture treatment. Estrogen receptor β has previously been 
shown to be co-localized with GnRH neurons, thereby indicating a direct action of 
estrogens on GnRH regulation (376), but no one had reported presence of AR in 
GnRH neurons. Here we demonstrated a co-localization of AR and GnRH neurons 
that further strengthens the hypothesis of a direct androgenic regulatory control on 
GnRH neurons. Hence, we have indications that both the GnRH abnormalities as 
well as the effect of electro-acupuncture could be mediated via the AR in 
hypothalamus. Moreover, previous experiments have demonstrated that levels of 
circulating estradiol is not altered in the DHT-induced rat PCOS model, which further 
supports the conclusion that we are looking at an androgenic effect (39).  
Although arcuate nucleus is considered to the principal location of the GnRH pulse 
generator in the rat brain, the preoptic area regulates the GnRH secretion surge 
controlling the preovulatory LH surge (299, 377) making our findings in MPO even 
more interesting. Administration of androgens prenatally have previously been shown 
to increase LH pulsatility, without affecting pituitary responsiveness to GnRH, and to 
abolish the estrogen induced LH surge, which is indicative of acceleration in the 
GnRH pulse generator. A contemporary reduction of estradiol induced progesterone 
receptor (PR) expression in the preoptic area was then considered evidence of how 
androgens could mediate this effect (330). 4-day of androgen administration to adult 
rats produced similar results on the LH surge and PR expression, but with the 
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contrast of an instead decreased LH and possibly GnRH secretion, similar to the male 
response (378, 379) and in oppose to human PCOS. These results are indicative of a 
programming effect (defect) of androgens during prenatal development that is 
different from the direct effects of hyperandrogenemia in adult life. Since our rats are 
exposed to androgens on day 21, it is possible that they have reduced GnRH 
secretion, with abolished GnRH/LH surges (378, 379). One might therefore speculate 
that restoration of the GnRH and LH surge by effects on the androgen receptor in 
the MPO could be, at least part of, the mechanism behind the improved estrous 
cyclicity after electro-acupuncture. Our succeeding study could not confirm the 
affected hypothalamic GnRH and AR expression, but there we only measured mRNA 
and not protein expression (371). This could mean that the effect is related to post 
translational events rather than gene expression changes. 
Lack of effect on LH-pulsatility in PCOS women 
The effect of acupuncture on the hypothalamic aberrations in the DHT-induced rat 
PCOS model and the initial finding that 14 acupuncture treatments improve 
menstrual bleeding pattern and reduced circulating total testosterone made us wonder 
whether the improved cyclicity in PCOS women is due to restoration of gonadotropin 
secretion or whether it is an effect at the ovarian level. To attend this hypothesis in the 
clinical situation we analyzed LH pulsatility in our PCOS women. Since LH pulsatility 
is known to decrease by obesity (72), we only included women with a BMI less than 
30.  
None of the LH pulsatility measures were affected by acupuncture treatment twice a 
week during 3 months. Instead the major effect accompanying the higher ovulation 
frequency and reduced circulating inhibin B levels in the acupuncture group was the 
general decrease in circulating sex steroids, androgen precursors and glucuronidated 
androgen metabolites after treatment, again pointing towards an effect at ovarian and 
adrenal level. However, it does not exclude involvement of central control 
mechanisms. 
The lack of effect on LH pulsatility and secretion pattern may also be due to the 
statistical limitation caused by too many drop outs. It could otherwise simply mean 
that the mechanism is concealed elsewhere. One reason behind the lack of effect on 
the LH pulsatility and secretion pattern may also be the sampling timing in the 
menstrual cycle, which could be a confounding factor (81, 262, 380). In a normal 
menstrual cycle, the LH frequency and amplitude increases in late follicular phase 
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(381, 382) and is more similar to the constant high LH frequency and amplitude in 
found PCOS.  The majority of endpoint overnight blood sampling was performed 
during cycle day 8–10 (mid to late follicular phase), and only 6 were performed 
independent of cycle day (4 in the control and 2 in the acupuncture group). It is 
possible that the if the higher ovulation frequency induced by acupuncture was due to 
a normalization of gonadotropin secretion with a conventional slowing of the LH 
pulsatility frequency during the luteal and early follicular phase followed by a normal 
increase in pulsatility in the late follicular phase, a possible treatment effect might have 
been more prominent if blood samplings were performed in early follicular phase. In a 
recent RCT comparing sham and true acupuncture in PCOS women the LH:FSH 
ratio was decreased in both groups together with rather high ovulation frequencies 
(372). Our data reflected a similar difference for both LH and LH:FSH ratio when 
comparing delta change between groups. But our LH pulsatility and secretion 
measures, despite randomization, incorporated baseline group differences in these two 
measures. When we corrected for these differences we found no treatment effect. 
Conjunction point for reproductive and neuroendocrine effects 
The causality of the presented data regarding changes in ovulation and sex steroids is 
difficult to determine. The reduction of androgen levels by normalization of intrinsic 
ovarian aberrations may calm the exaggerated follicular growth, restore the follicle 
maturation processes and hence lead to ovulation (50). It could also be the other way 
around, that improved ovulation, possibly caused by external factors, restores 
follicular growth and/or aberrations and thereby reduces androgen levels due to the 
lower pool and/or activity of androgen producing cells (68). This is in line with the 
tendency towards reduced number of antral follicles and ovarian volume after 
acupuncture. We performed correlation analyses between ovulation and endpoint 
variables, in the whole material, to see which variables that were associated with 
ovulation. Estrone, estradiol and androstane-3α, and 17-diol-3-glucuronide were all 
associated with ovulation, but none of the LH variables. The involvement of 
sympathetic nervous system and an alteration in neurogenic control of the ovary has 
been implicated in PCOS etiology (278, 279, 383, 384). One hypothetical mediator for 
that effect, combining an autonomic and ovarian effect, is nerve growth factor (NGF).  
Ovarian NGF production is increased in the follicular fluid in women with PCOS and 
in an estradiol valerate induced rat PCOS model (213, 385, 386).  Overexpressing 
NGF in the ovaries of a transgenic mice model results in ovarian hyperinnervation, 
arrested follicle growth and increased ovarian steroidal responsiveness to 
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gonadotropins (213). Electro-acupuncture has been shown to decrease high ovarian 
NGF in the estradiol valerate PCOS model (385, 386), as well as decrease several 
markers of sympathetic activity in adipose tissue of the DHT model (340). Together 
with our microneurography measurements demonstrating decreased high muscle 
sympathetic activity after 14 acupuncture treatments, this indicates the involvement of 
the sympathetic nervous system in both PCOS etiology and the mechanistic effect of 
acupuncture (217).  β-endorphin, an opioid, is known to modulate sympathetic tone 
(387, 388) and have inhibitory effect on GnRH release, and GnRH secretion has been 
shown to be increased in PCOS (288, 291, 298).  That naltrexone, a μ-receptor 
antagonist induces ovulation and decreases LH concentration further indicates the 
role of β-endorphin in PCOS (310-312). That similar effects are also mediated by 
electro-acupuncture (314-316) concurrent with a lowering of β-endorphin levels (314) 
implies the involvement of the opioid system in the underlying mechanism. This is 
also supported in our recent experimental study where electrical stimulation of the 
acupuncture needles affected the expression of opioid receptors μ and κ in rat 
hypothalamus, together with improved cyclicity and reduction of testosterone levels 
(371). That acupuncture had an effect on both adrenal and ovarian originating sex 
steroids in paper II favor a central mechanism controlling the effect of acupuncture.  
Altogether, both the clinical and experimental data in this thesis support that 
acupuncture has a beneficial effect on ovulation which is related to decreased levels of 
sex steroids, their precursors and glucuronidated androgen metabolites, and inhibin B. 
Although the clinical data does not support changes in LH pulsatility/secretion 
pattern as a possible mediator for this effect, there is strong evidence of central 
components that probably involve both opioid and sympathetic activity, an effect that 
most likely is mediated via the androgen receptor. 
 
Acupuncture on metabolic function (paper III-IV) 
The association between PCOS and insulin resistance and compensatory 
hyperinsulinemia, and the increased risk of type 2 diabetes and possibly CVD 
definitely demands attention (42, 167-169, 172). Insulin resistance, occurring also in 
the lean PCOS women and aggravating both endocrine and metabolic features and 
the effect of acupuncture were here investigated in the DHT-induced rat PCOS 
model. We have previously demonstrated improved insulin sensitivity after both 
acupuncture and exercise (317). Here we aimed to investigate the effect of more 
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frequent acupuncture treatments on insulin sensitivity and to compare the effect of 
manual and electrical stimulation of the acupuncture needles. 
Acupuncture improves insulin sensitivity 
Whole body insulin sensitivity and glucose tolerance in the DHT-induced rat PCOS 
model was measured with the golden standard euglycemic hyperinsulinemic clamp 
method and the oral glucose tolerance test (OGTT). Rats responded to electro-
acupuncture treatment five days per week with a normalization of insulin sensitivity, 
measured by the clamp, with no concurrent improvements in body composition. This 
was an enhancement of the effect seen in the previous experiments when animals 
were treated three days per week (317). Next we aimed to elucidate whether low-
frequency electrical acupuncture stimulation used in the previous trial is more effective 
than manual stimulation of the needles in the improvement of insulin sensitivity. In 
this experiment we avoided the clamp since we aimed to analyze protein expression in 
a basal non-insulin stimulated state. Instead we used the OGTT where we surprisingly 
enough found no treatment effect after electrical stimulation. Previous studies have 
reported improved glucose tolerance, although acutely and in male rats (389-391). 
However, after electrical stimulation we saw a decrease in inguinal fat mass. After 
manual stimulation we found no effect on OGTT AUC but decreased fasting and 
120-min glucose levels as well as increased glucose clearance, without changes in 
insulin levels. This implies at least partly improved glucose tolerance and /or 
improved hepatic insulin sensitivity or decreased pancreatic glucagon release by 
manual acupuncture. It might also be reflective of improved insulin sensitivity. The 
discrepancy between the clamp and OGTT data in the same DHT-induced rat PCOS 
model may have several causes. Primarily, although OGTT data is correlated with 
clamp measured insulin sensitivity, it doesn’t have the precision for quantitatively 
measure insulin sensitivity, and includes both glucose effectiveness and insulin 
sensitivity in oppose to the clamp which only measures the latter (192, 357, 392). 
Other explanations may be the different levels of insulin as well as the duration of 
insulin stimulation in the two experiments. The high insulin levels in the clamp may 
reflect improved insulin responsiveness, while the probably lower insulin levels in the 
OGTT reflect no change in insulin sensitivity or glucose tolerance by electrical 
stimulation of the acupuncture needles. The long duration of the clamp is also more 
likely to suppress hepatic glucose production and avoid underestimation of the 
amount of glucose that is metabolized. Another issue is that in the OGTT we did not 
take cycle stage into account as we did in the clamp experiment. Since insulin 
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sensitivity is known to fluctuate over the cycle this may be a confounding factor (346, 
347). 
Acupuncture affects molecular signaling pathways 
Insulin or contraction stimulated glucose uptake in skeletal and adipose tissue is 
dependent on GLUT4 translocation to the plasma membrane (183, 393). In paper III 
we measured gene and protein expression of some key molecules in the insulin 
signaling cascade. After electro-acupuncture we found increased insulin stimulated 
GLUT4 protein expression, both in the plasma membrane and cytosol of skeletal 
muscle cells, as measured with western blot and immunohistochemistry. Moreover, no 
change in Akt or AS160 activation was recognized. This indicated that the improved 
insulin sensitivity was regulated by increased GLUT4 translocation capacity, but 
perhaps not via the traditional insulin signaling pathway. Levels of GLUT4 protein 
after acute electro-acupuncture have previously been shown to be increased in insulin 
resistant male rats, without insulin stimulation (394). On the other hand, a possible 
change in AKT and/or AS160 activation might have been masked by the maximum 
stimulation of high insulin levels in the clamp (199, 200).  
In the following study (paper IV) in which we compared electrical and manual 
acupuncture stimulation, we measured gene and protein expression in both skeletal 
muscle and adipose tissue, in a non insulin-stimulated state. The final acupuncture 
treatment was given one hour before tissue collection. A summary of the western blot 
results of paper IV is presented in figure 8. Although we found no effect of on 
glucose tolerance by electrical stimulation, protein expression of several key molecules 
related to insulin sensitivity was regulated in the non insulin stimulated state. Levels of 
GLUT4 protein was measured with gene expression, western blot and IHC analyses.  
No changes were detected on GLUT mRNA expression levels, neither after manual 
nor electrical stimulation in adipose tissue or skeletal muscle. Moreover, total GLUT4 
protein content, measured by western blot, revealed no changes in adipose tissue after 
either treatment modalities. GLUT4 protein content in skeletal muscle, on the other 
hand, was decreased by electrical but not manual stimulation, indicating lower glucose 
transport after electrical stimulation. However, GLUT4 protein content measured by 
IHC revealed increased expression in all cell compartments in skeletal muscle after 
both manual and electrical stimulation, with more intense signal after electrical 
stimulation. No such effect was seen in adipose tissue. Therefore, we hypothesized 
that electrical stimulation has stronger effect on translocation than expression in 
 | Key results and discussion 75 
 
skeletal muscle, with no effect on adipose tissue. The discrepancy to the increased 
GLUT4 protein expression in skeletal muscle after the clamp may be explained by the 
clamps high insulin levels of long duration, driving also protein expression.  
Figure 8. Summary of non-insulin stimulated western blot results on Nr4a3, Tbc1D1 and AS160 
after 4-5 weeks of manual and electrical acupuncture in dihydrotestosterone treated female rats. Akt: 
protein kinase B , IRS-1: insulin receptor substrate 1, GLUT4: Glucose transporter 4, PI3K: 
phosphatidylinositol 3-kinase, AMPK: 5' adenosine monophosphate-activated protein kinase. 
Protein levels of Nr4a3 and activation of AS160 (pAS160/S160 ratio), proteins 
involved in GLUT4 translocation, was simultaneously increased in skeletal muscle by 
electrical acupuncture stimulation. Nr4a3 has been implicated in insulin sensitivity and 
oxidative metabolism, and increased levels aid insulin to stimulate glucose transport 
and GLUT-4 translocation. Contractile activity has also previously been shown to 
increase mRNA levels of Nr4a3, probably mediated by AMPK, which supports our 
results (395-397). Similar results are reported after treatment with β-adrenergic 
agonists indicating a sympathetic control (397). As mentioned before, AS160 may be 
the link where insulin signaling and insulin independent signaling for glucose uptake 
converge (177, 184). Our findings of increased levels of both Nr4a3 and AS160 in 
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skeletal muscle after electrical stimulation, in the basal non insulin-stimulated state, is 
therefore in compliance with improvements in several theoretical pathways of insulin-
independent glucose uptake. After manual stimulation we found decreased protein 
levels of Nr4a3 in mesenteric fat, but this was not supported by gene expression and 
its functionality may be questioned since we found no change in GLUT4 expression 
or translocation. 
Efficacy and mechanisms of manual and electrical stimulation 
The mechanism of acupuncture on the metabolic function is highly speculative, but it 
has been related to adrenal β-endorphin secretion to stimulate insulin secretion, 
cholinergic nerves, pancreatic nitric oxide synthase and somatic afferent nerves (391, 
398, 399). Our results indicate that the effect of acupuncture on insulin sensitivity 
seems to be directed to skeletal muscle. However, we did see increased gene 
expression of MAPK3, Glycogen synthase kinase 3 beta (Gsk3b) and adenylate 
cyclase 3, proteins all involved in insulin sensitivity (400-403), in adipose tissue 
although these were not confirmed by western blot measurements. Therefore, we 
cannot exclude that the improved insulin sensitivity also involves regulatory 
mechanisms in adipose tissue. When evaluating the magnitude of manual and 
electrical stimulation and the effect on insulin sensitivity in the current setting we 
found stronger beneficial effects of electrical stimulation, with support from the 
clamp, protein and IHC data. On the other hand, manual stimulation had a partly 
positive effect on glucose tolerance and on gene expression in adipose tissue although 
we found no functional molecular evidence to support the mechanism. Adding up 
with our later data on estrous cyclicity where we did not see a difference between the 
groups after the two stimulation modalities we cannot consider electrical stimulation 
to be superior than manual in all aspects (371). Importantly, the differences between 
the two stimulation modalities could reflect differences in stimulation duration, given 
that needles were manually stimulated every 5 min by compared with continuous low-
frequency electrical stimulation. Of importance to mention is that the results 
presented in this thesis regarding insulin sensitivity is only based on animal 
experimental data and not on clinical evidence, in contrast to the results on 
reproductive function. Our previous clinical study measuring insulin sensitivity with 
the euglycemic hyperinsulinemic clamp found no effect of either acupuncture or 
exercise (404). This may be due the low intensity and frequency of the interventions. 
It remains to elucidate whether an increased number or treatment frequency, could 
affect metabolic variables such as insulin sensitivity. 
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GENERAL DISCUSSION 
 
The data presented in this thesis show that acupuncture have beneficial effects on 
both reproductive and metabolic function, without any effect on anthropometrics as 
an explanatory factor. This is derived from both experimental animal data and a 
human PCOS study. Importantly, the main difference between these two 
experimental studies is that the DHT-induced PCOS rats are mainly hyperandrogenic, 
since DHT cannot be converted to estrogen, and therefore we focus on the alterations 
that are represented by androgens. Human PCOS is more complex with possible 
effects from estrogens and androgen metabolites. Therefore, the conclusions from the 
animal data cannot be completely translated to the clinical situation. On the other 
hand, the animal studies gave us the opportunity to investigate the androgenic effect 
within the hypothalamus. This provided us with evidence that androgens may 
influence GnRH secretion and that acupuncture regress these alterations which may 
explain improved estrous cyclicity. The acupuncture situation is also easier to control 
for when using animals, since they don’t have the influence of treatment expectancies.  
When designing a clinical study it is of importance to decide what to control for. In 
pharmaceutical studies the standard procedure is to use a placebo. For non-
pharmaceutical interventions such as exercise, acupuncture and most likely 
psychotherapy the control is more complicated where a true placebo is not available. 
In paper II we decided to control for the time and attention involved in the 
therapeutic meeting of acupuncture treatments. We used an attention control group 
instead of any “placebo needle” or minimal acupuncture treatment that is not 
completely inert, but neither with this solution we implicate that it is placebo 
controlled. In paper IV we chose to mimic the clinical situation, where acupuncture 
treatment is performed by a combinatory treatment where some needles are 
stimulated electrically and some manually. Electrical stimulation of needles is normally 
continuous while the manual needle stimulation is intermittent and we aimed to 
elucidate if those two treatments have different mechanistic effects. Our present data 
and the subsequent study indicate that electrical stimulation may be more effective 
than manual stimulation, but perhaps not in all aspects (371). We cannot though 
exclude that these results are mainly time-dependent due to the intermittent nature of 
manual stimulation, especially since we also see that the effect of acupuncture is dose-
responsive (233, 317, 373). To further elucidate the efficacy one would have to 
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perform intermittent electrical stimulation equalized to the manual stimulation or 
continuous manual stimulation. Another issue to discuss is the treatment frequency. 
We gave our DHT-induced PCOS rats acupuncture 5 days per week and the women 
twice per week. Neither of these treatment frequencies are probably achievable long 
term in clinic. On the other hand, even though the effect appears to be dose-
dependent, when looking at previous data, we also see that it is long-lasting (233, 404). 
This implies that a period with more frequent treatment to gain a wanted effect may 
well be followed by less frequent maintenance treatments as usually common in the 
clinic. 
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CONCLUDING REMARKS AND FUTURE 
PERSPECTIVES 
 
cience is nothing but perception, Plato said. I try to keep in mind that 
our “truth” is simply the best way of describing the data we currently 
possess. Science is a field of constant update, where hypotheses and 
theories are established simply to later be rejected. One cannot know how long 
our truth will stand unchallenged. Furthermore, lack of an effect does not 
necessary equals no effect. 
The results of the papers presented in this thesis indicate that acupuncture with 
manual and electrical stimulation elicits local and systemic effects on insulin sensitivity 
and reproductive function and may represent a supplement or alternative to the 
traditional treatments. The key results of this thesis are: 
 
 Acupuncture improves ovulation frequency and regulates sex steroid 
production rather than gonadotropin secretion in PCOS women. 
 
 Electro-acupuncture in DHT-induced PCOS rats improves estrous 
cyclicity. Moreover, there is a co-localization of the nuclear 
androgen receptor with GnRH in the hypothalamus, and the effect 
of acupuncture is related to normalization of hypothalamic 
aberrations that probably are mediated by androgen receptor 
activation. 
 
 Both electrical and manual stimulation have beneficial effects on 
metabolic function in DHT-induced PCOS rats. Electro-
acupuncture normalizes insulin sensitivity and regulates insulin 
sensitivity related protein expression, while manual acupuncture 
partly improves glucose tolerance but do not regulate key signaling 
pathways to the same extent. 
 
S 
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 The present data indicates that electrical stimulation is superior to 
manual stimulation, although the effects may be mediated via 
differential regulatory mechanisms. 
The viscous circle, driven by androgens, insulin or other factors, must be broken to 
improve the health status of women with PCOS. Although pharmaceutical 
alternatives may be effective, they are also associated with negative side-effects (264). 
The results of this thesis further strengthen the idea of acupuncture as a potential 
treatment option for both the reproductive and metabolic disturbance in PCOS. 
Although we here provide some answers there are more questions to be dealt with. 
We have repeatedly shown in both clinical and animal experimental studies that 
acupuncture is beneficial for ovulatory dysfunction in PCOS. For the purpose of 
implementing acupuncture in the conventional treatment strategy, though, it is of 
importance to compare it with the first line pharmaceutical options. This is important 
for the support and sanction of acupuncture as a treatment method. We are now 
involved in a multicenter clinical study comparing the effect of acupuncture versus 
clomiphene citrate on live birth rate and ovulation in anovulatory women with PCOS 
that will address this question. The effect on metabolic function has only, but 
repeatedly, been demonstrated in animal experimental studies. We have now started a 
clinical study in which we aim to translate our experimental findings into women with 
PCOS with the hypothesis that acupuncture improve insulin sensitivity and regulates 
key signaling molecular pathways in skeletal muscle and adipose tissue. To further 
investigate the underlying mechanisms of the beneficial effects may also be supportive 
in the search for other possible alternative treatments, including pharmacological. The 
mechanism is probably dual with one acute effect and another long term. The data in 
this thesis are representative of the long term mechanism, but we are currently 
conducting experimental studies where we investigate the acute effects on insulin 
sensitivity of both manual and electrical acupuncture. As mentioned earlier studies 
comparing intermittent electrical with manual stimulation could also better answer the 
efficacy of the two. There is evidence that the effect of acupuncture is mediated via 
the opioid and sympathetic nervous system (210, 307, 314). To further investigate the 
involvement of the sympathetic, parasympathetic and opioid system we also plan to 
perform acupuncture studies where we will block these different systems.  
Altogether, the current thesis has demonstrated that acupuncture have beneficial 
effects on reproductive and possibly also metabolic function and may represent a 
therapeutic option for PCOS. Continuously, more and more evidence are gathered, 
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supporting the efficacy of acupuncture. Interesting it will be, to follow/be part of this 
development, with the possible use of acupuncture as a represented treatment in 
PCOS. 
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